<article article-type="research-article" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Immunol Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Immunol Immunother</journal-id><journal-id journal-id-type="pmc-domain-id">4569</journal-id><journal-id journal-id-type="pmc-domain">cii</journal-id><journal-title-group><journal-title>Cancer Immunology, Immunotherapy : CII</journal-title></journal-title-group><issn pub-type="ppub">0340-7004</issn><issn pub-type="epub">1432-0851</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12847509</article-id><article-id pub-id-type="pmcid-ver">PMC12847509.1</article-id><article-id pub-id-type="pmcaid">12847509</article-id><article-id pub-id-type="pmcaiid">12847509</article-id><article-id pub-id-type="pmid">41591499</article-id><article-id pub-id-type="doi">10.1007/s00262-025-04287-7</article-id><article-id pub-id-type="publisher-id">4287</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Risk factors and outcomes for steroid-refractory immune-related hepatotoxicity in locally advanced and metastatic cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="S">Songlin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yuekai</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guan</surname><given-names initials="Y">Yaping</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xie</surname><given-names initials="H">Hong</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dong</surname><given-names initials="Y">Yue</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chang</surname><given-names initials="J">Jiang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xie</surname><given-names initials="Q">Qi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="B">Baocheng</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="J">Jun</given-names></name><address><email>ggjun2005@126.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label>School of Clinical Medicine, Shandong Second Medical University, Weifang, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03wnrsb51</institution-id><institution-id institution-id-type="GRID">grid.452422.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0604 7301</institution-id><institution>Department of Oncology, </institution><institution>The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, </institution></institution-wrap>Jinan, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03wnrsb51</institution-id><institution-id institution-id-type="GRID">grid.452422.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0604 7301</institution-id><institution>Shandong Lung Cancer Institute, </institution><institution>The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, </institution></institution-wrap>Jinan, China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03wnrsb51</institution-id><institution-id institution-id-type="GRID">grid.452422.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0604 7301</institution-id><institution>Lung Cancer Center, </institution><institution>The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, </institution></institution-wrap>Jinan, China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/014335v20</institution-id><institution-id institution-id-type="GRID">grid.476817.b</institution-id><institution>Department of Oncology, </institution><institution>The 960 Hospital of the People’s Liberation Army, </institution></institution-wrap>Jinan, China </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>1</month><year>2026</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2026</year></pub-date><volume>75</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">506253</issue-id><elocation-id>43</elocation-id><history><date date-type="received"><day>11</day><month>11</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>29</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-29 20:25:13.250"><day>29</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© The Author(s) 2026</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref content-type="ccbyncndlicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="262_2025_Article_4287.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract id="Abs1"><p id="Par1">Immune-related hepatotoxicity (IRH) is one of the common immune-related adverse events caused by immune checkpoint inhibitors (ICIs). Some patients with steroid-refractory IRH (Ref-IRH) are potentially life-threatening. This study was designed to determine the risk factors and outcomes for Ref-IRH. Locally advanced or metastatic cancer patients who developed steroid-responsive IRH (Res-IRH) or Ref-IRH were identified between December 1, 2019 and September 1, 2024. Patient characteristics, peripheral blood biomarkers, and cytokine levels were collected. In this cohort of 480 patients treated with immune checkpoint inhibitors, 35 patients (7.3%) developed IRH, including 12 with Res-IRH and 13 with Ref-IRH. Patients with Ref-IRH were more likely to be hepatocellular carcinoma (<italic toggle="yes">p</italic> = 0.035), receive ICIs plus targeted therapy (<italic toggle="yes">p</italic> = 0.046), and have higher CTCAE grades (<italic toggle="yes">p</italic> = 0.044) at diagnosis. Patients with Ref-IRH had lower platelet counts (<italic toggle="yes">p</italic> = 0.006), higher procalcitonin levels (<italic toggle="yes">p</italic> = 0.012), and higher IL-6 levels (<italic toggle="yes">p</italic> = 0.038). Univariate logistic regression analysis indicated that higher IL-6 at diagnosis was a potential risk factor for Ref-IRH (<italic toggle="yes">p</italic> = 0.019). All Ref-IRH patients were treated with immunosuppressive agents. The survival outcomes of Ref-IRH were comparable to those of Res-IRH. Patients with Ref-IRH were unlikely to quickly recover with a longer time from initial diagnosis of IRH to resolution to grade 1 (<italic toggle="yes">p</italic> = 0.002), from peak ALT (<italic toggle="yes">p</italic> = 0.007), AST (<italic toggle="yes">p</italic> = 0.011), and TBIL (<italic toggle="yes">p</italic> = 0.048) to resolution to grade 1, from initial diagnosis of IRH to use of prednisone ≤ 20 mg/day (<italic toggle="yes">p</italic> = 0.025), and prolonged hospital length of stay (<italic toggle="yes">p</italic> = 0.017). In conclusion, high IL-6 at diagnosis is a potential risk factor for the development of Ref-IRH. There was no significant difference in efficacy and survival between patients with Ref-IRH and Res-IRH, but much more time from the initial diagnosis of IRH to resolution to grade 1 and the use of immunosuppressive agents is needed for Ref-IRH patients.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00262-025-04287-7.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Programmed cell death protein-1</kwd><kwd>Immune checkpoint inhibitor</kwd><kwd>Immune-related adverse events</kwd><kwd>Immune-related hepatotoxicity</kwd><kwd>Steroid-responsive</kwd><kwd>Steroid-refractory</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81572875</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100007129</institution-id><institution>Natural Science Foundation of Shandong Province</institution></institution-wrap></funding-source><award-id>ZR2021MH291</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Cultivating Fund of The First Affiliated Hospital of Shandong First Medical University</institution></funding-source><award-id>QYPY2022NSFC0613</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>CSCO-MSD Cancer Research Foundation</institution></funding-source><award-id>Y-MSD2020-0350</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>CSCO-PILOT Cancer Research Foundation</institution></funding-source><award-id>Y-2019AZMS-0440</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Wu Jieping Medical Foundation for Clinical Scientific Research</institution></funding-source><award-id>320.6750.2020-12-16</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer-Verlag GmbH Germany, part of Springer Nature 2026</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par35">Treatment with immune checkpoint inhibitors (ICIs), including cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, has achieved extraordinary response rates and has become a standard systematic treatment for patients with various malignancies in early or advanced stages [<xref ref-type="bibr" rid="CR1">1</xref>]. However, T-cell dysregulation by ICIs can lead to the development of autoimmune manifestations, referred to as immune-related adverse events (irAEs). With the widespread application of ICIs, irAEs can occur in any organ, including the skin, endocrine system, liver, lung, and kidney, with an incidence of 54–76% [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par36">Immune-related hepatotoxicity (IRH) represents one of the common irAEs and varies in severity from mild to life-threatening. IRH typically presents with liver or bile duct injury along with elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) with or without concurrent elevated total bilirubin (TBIL) [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. The clinical management of IRH is based on expert opinion according to local and international guidelines, including the ASCO, SITC, and NCCN guidelines [<xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR8">8</xref>]. Most grade ≥ 2 IRHs respond well to treatment with high-dose systemic corticosteroids with various time to resolution. However, some patients with IRH can present with a phenotype of steroid-refractory IRH (Ref-IRH) which does not improve after 5–7 days of corticosteroids or reoccurs under corticosteroid treatment [<xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR8">8</xref>]. Use of increased dose of corticosteroids provides no additional benefit in terms of the time to resolution [<xref ref-type="bibr" rid="CR9">9</xref>]. These patients are recommended to discontinue ICI treatment and receive additional immunosuppressants including mycophenolate mofetil (MMF), tacrolimus (TAC), intravenous immunoglobulin (IVIG), or azathioprine, on the basis of on published guidelines [<xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR8">8</xref>]. Retrospective investigations revealed that 23–48% of IRH patients were treated with additional immunosuppressive agents [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. A recent systematic review and meta-analysis showed that a summary estimate of the proportion of patients with steroid-refractory hepatitis in a random effects model was 16% [<xref ref-type="bibr" rid="CR11">11</xref>]. However, the incidence of Ref-IRH is unknown. Although successful treatments with various immunosuppressive agents for Ref-IRH have been widely reported in case series, the efficacy of immunosuppressive agent monotherapy or combination therapy for Ref-IRH is not clear [<xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR18">18</xref>]. Thus, this retrospective cohort study was designed to determine the risk factors and treatment outcomes for Ref-IRH with immunosuppressive agents in a variety of cancer types.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Patient cohort</title><p id="Par37">We retrospectively reviewed a cohort of patients with locally advanced and metastatic cancer who presented to the First Affiliated Hospital of Shandong First Medical University and were treated with ICIs from December 2019 to September 2024. The inclusion criteria were as follows: age older than 18 years; histologically or cytologically confirmed locally advanced or metastatic solid cancer according to the American Joint Committee on Cancer (AJCC) staging system, 8th version; receiving PD-1/PD-L1 inhibitor monotherapy (nivolumab, pembrolizumab, camrelizumab, sintilimab, tislelizumab, durvalumab, or atezolizumab) or a combination with CTLA-4 inhibitor, chemotherapy, or targeted therapy, as a first-, second- or later-line treatment for at least one tumor evaluation by imaging; and having an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2. Patients whose response to therapy was not evaluated after the initiation of immunotherapy were excluded.</p></sec></sec><sec id="Sec4"><title>Evaluation of efficacy and safety</title><p id="Par38">The objective response by radiographic findings was assessed as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) according to RECIST 1.1. The objective response rate (ORR) was defined as the proportion of patients who achieved a CR or PR to immunotherapy. The disease control rate (DCR) was defined as the percentage of patients who achieved a CR, PR, or SD after immunotherapy. The diagnosis of IRH was conducted by the treating medical oncologist and confirmed by a local multidisciplinary team. Briefly, IRH diagnosis was based on a combination analysis of patients’ history, examination, symptoms, radiographic findings, blood parameters, and biological tests and a lack of evidence of tumor progression in the liver, virus infection, and pre-existing autoimmune hepatitis. We evaluated the clinical severity of all irAEs and IRH according to the Common Terminology Criteria for Adverse Events, version 5.0. AST/ALT grades 1 to 4 correspond to &lt; 3 × upper limit of normal (ULN), 3–5 × ULN, 5–20 × ULN, and &gt; 20 × ULN in order, respectively, whereas TBIL corresponds to &lt; 1.5 × ULN, 1.5–3 × ULN, 3–10 × ULN, and &gt; 10 × ULN, respectively. To identify liver injury patterns, the R-value is calculated by comparing ALT and alkaline phosphatase (ALP) levels to their upper normal limits. Based on the R-value, liver injury patterns can be classified as hepatocellular, cholestatic, or mixed. The pattern of injury was based on the <italic toggle="yes">R</italic> factor to differentiate a hepatocellular, cholestatic, or mixed pattern of injury. The treatment threshold for starting an escalation of IRH varied by clinical context but was in line with international and local guidelines. IRH that did not improve after 5–7 days of corticosteroid treatment or reoccurred under steroid treatment was considered Ref-IRH. Improvement with corticosteroids or immunosuppressive agents was defined as ALT and AST levels falling below 5 × ULN by day 7, and TBIL levels falling below 1.5 × ULN by day 5. In contrast, worsening was defined as the failure to achieve these biochemical thresholds.</p></sec><sec id="Sec5"><title>Clinical annotation</title><p id="Par39">Data were gathered through electronic patient records and oncology databases. The baseline clinical characteristics of these patients included age, sex, ECOG PS, smoking status, histology, tumor node metastasis (TNM) stages, complete blood counts, proteins, and cytokines at the start of treatment. Liver function, protein, and cytokine levels were also analyzed at the time of IRH diagnosis. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), eosinophil-to-lymphocyte ratio (ELR), monocyte-to-lymphocyte ratio (MLR), and systemic immunity-inflammation index (SII) were calculated on the basis of the results of the baseline complete blood test. The NLR, PLR, ELR, and MLR were calculated by dividing the absolute neutrophil, platelet, eosinophil, and monocyte counts, respectively, by the lymphocyte counts. The calculation of the SII is based on the following formula: SII = platelet count × neutrophil count/lymphocyte count. The levels of cytokines including interleukin (IL)-2, IL-4, IL-6, IL-10, interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α) were determined via the enzyme-linked immunosorbent assay (ELISA) using Human Cytokine Standard Assays Panel (ET Healthcare, Inc., Shanghai, China) according to the manufacturer’s instructions. Progression-free survival (PFS) was defined as the date of immunotherapy initiation to the date of disease progression or death from any cause, whichever occurred first. Patients who were alive without disease progression were censored on the date of their last disease assessment. Overall survival (OS) was defined as the time from immunotherapy initiation to death from any cause. Patients who were still alive were censored at the date of last contact. This study was approved by the independent research ethics committee of the First Affiliated Hospital of Shandong First Medical University (NO: YXLL-KY-2022–059) and conformed to the principles of the Declaration of Helsinki.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par40">Categorical variables are reported as frequencies and percentages. Quantitative patient variables are presented as medians and ranges. For categorical variables, we used Fisher’s exact test to compare patient characteristics among different groups. For continuous variables, independent sample t tests or Mann‒Whitney U tests were used to compare patient groups. Univariable logistic regression was used to analyze the relationships between patient variables and the development of Ref-IRH. Survival outcomes were estimated via Kaplan–Meier curves and the log-rank test. The hazard ratio (HR) was estimated via Cox proportional hazards regression models. To confirm that the differences in Kaplan‒Meier survival curves between patients with and without IRH were not attributable to time bias, we adopted the 3-month landmark analysis method according to our previous report [<xref ref-type="bibr" rid="CR3">3</xref>]. In this analysis, we excluded patients who experienced events within 3 months of the initiation of ICI therapy, as well as those who developed IRH after 3 months of ICI therapy initiation. Statistical analyses were performed via GraphPad Prism version 9 (GraphPad Software, San Diego, CA, USA), and SPSS 26.0 software (SPSS Inc., Chicago, IL, USA) was used for all the statistical tests. All the statistical tests were two-tailed, and <italic toggle="yes">p</italic> &lt; 0.05 was considered statistically significant.</p></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>The incidence of Res-IRH and Ref-IRH</title><p id="Par41">In this pan-tumor cohort, which included 530 locally advanced and metastatic cancer patients who received immunotherapy, 50 patients were excluded because they were lost to follow-up. Finally, 480 patients were included in this study. A total of 160 patients (33.3%) were developed non-IRH irAEs. A total of 35 patients (7.3%) had IRH, including 10 patients with G1 IRH who did not require steroid treatment and 25 with G2-4 IRH who required steroid treatment (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). Among patients with G2-4 IRH, 12 developed Res-IRH, and 13 developed Ref-IRH. The median age was 64.0 years for patients with IRH and 61.0 years for patients without IRH. The median age was 65.5 years for patients with Res-IRH and 64.0 years for patients with Ref-IRH (Table <xref ref-type="table" rid="Tab1">1</xref>).<fig id="Fig1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Flow chart showing cohort selection. ICIs: immune checkpoint inhibitors; irAEs: immune checkpoint inhibitor-related adverse events; IRH: immune-related hepatotoxicity; Res-IRH: steroid-responsive immune-related hepatotoxicity; Ref-IRH: steroid-refractory immune-related hepatotoxicity</p></caption><graphic id="MO1" orientation="portrait" position="float" xlink:href="262_2025_4287_Fig1_HTML.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><table-wrap id="Tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical characteristics of enrolled patients at diagnosis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Characteristic</th><th align="left" colspan="1" rowspan="1">IRH (<italic toggle="yes">n</italic> = 35)</th><th align="left" colspan="1" rowspan="1">Non-IRH (<italic toggle="yes">n</italic> = 445)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic></th><th align="left" colspan="1" rowspan="1">Res-IRH (<italic toggle="yes">n</italic> = 12)</th><th align="left" colspan="1" rowspan="1">Ref-IRH (<italic toggle="yes">n</italic> = 13)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Mean age (range), years</td><td align="left" colspan="1" rowspan="1">64.0 (36.0–80.0)</td><td align="left" colspan="1" rowspan="1">61.0 (22.0–86.0)</td><td align="char" char="." colspan="1" rowspan="1">0.857</td><td align="left" colspan="1" rowspan="1">65.5 (41.0–80.0)</td><td align="left" colspan="1" rowspan="1">64.0 (49.0–71.0)</td><td align="char" char="." colspan="1" rowspan="1">0.309</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.457</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.073</td></tr><tr><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">26 (74.3)</td><td align="left" colspan="1" rowspan="1">300 (67.4)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">7 (58.3)</td><td align="left" colspan="1" rowspan="1">12 (92.3)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">9 (25.7)</td><td align="left" colspan="1" rowspan="1">145 (32.6)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">5 (41.7)</td><td align="left" colspan="1" rowspan="1">1 (7.7)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Smoking status</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.218</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.428</td></tr><tr><td align="left" colspan="1" rowspan="1">Current/former</td><td align="left" colspan="1" rowspan="1">20 (57.1)</td><td align="left" colspan="1" rowspan="1">201 (45.2)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">6 (50.0)</td><td align="left" colspan="1" rowspan="1">9 (69.2)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Never</td><td align="left" colspan="1" rowspan="1">15 (42.9)</td><td align="left" colspan="1" rowspan="1">244 (54.8)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">6 (50.0)</td><td align="left" colspan="1" rowspan="1">4 (30.8)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Primary malignancy</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.224</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.035</td></tr><tr><td align="left" colspan="1" rowspan="1">Lung cancer</td><td align="left" colspan="1" rowspan="1">9 (25.7)</td><td align="left" colspan="1" rowspan="1">101 (22.7)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">7 (58.3)</td><td align="left" colspan="1" rowspan="1">2 (15.4)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Gastric cancer</td><td align="left" colspan="1" rowspan="1">9 (25.7)</td><td align="left" colspan="1" rowspan="1">120 (27.0)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">4 (30.8)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Hepatocellular carcinoma</td><td align="left" colspan="1" rowspan="1">6 (17.1)</td><td align="left" colspan="1" rowspan="1">35 (7.9)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0 (0.00)</td><td align="left" colspan="1" rowspan="1">5 (38.5)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Others</td><td align="left" colspan="1" rowspan="1">11 (31.4)</td><td align="left" colspan="1" rowspan="1">189 (42.5)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">3 (25.0)</td><td align="left" colspan="1" rowspan="1">2 (15.4)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Liver metastasis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.019</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1"> &gt; 0.999</td></tr><tr><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">17 (48.6)</td><td align="left" colspan="1" rowspan="1">125 (28.1)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">6 (50.0)</td><td align="left" colspan="1" rowspan="1">6 (46.2)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">18 (51.4)</td><td align="left" colspan="1" rowspan="1">320 (71.9)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">6 (50.0)</td><td align="left" colspan="1" rowspan="1">7 (53.8)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">ICI type</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.008</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.593</td></tr><tr><td align="left" colspan="1" rowspan="1">Anti-PD-1/Anti-PD-L1</td><td align="left" colspan="1" rowspan="1">31 (88.6)</td><td align="left" colspan="1" rowspan="1">437 (98.2)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">10 (83.3)</td><td align="left" colspan="1" rowspan="1">12 (92.3)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Anti-PD-1 + Anti-CTLA-4</td><td align="left" colspan="1" rowspan="1">4 (11.4)</td><td align="left" colspan="1" rowspan="1">8 (1.8)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">1 (7.7)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Treatment regimen</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.012</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.046</td></tr><tr><td align="left" colspan="1" rowspan="1">Anti-PD-1/Anti-PD-L1 monotherapy</td><td align="left" colspan="1" rowspan="1">1 (2.9)</td><td align="left" colspan="1" rowspan="1">17 (3.8)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">0 (0.00)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">ICI + chemotherapy</td><td align="left" colspan="1" rowspan="1">21 (60.0)</td><td align="left" colspan="1" rowspan="1">359 (80.7)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">9 (75.0)</td><td align="left" colspan="1" rowspan="1">5 (38.5)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">ICI + targeted therapy</td><td align="left" colspan="1" rowspan="1">13 (37.1)</td><td align="left" colspan="1" rowspan="1">69 (15.5)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">3 (25.0)</td><td align="left" colspan="1" rowspan="1">8 (61.5)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Treatment line</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.012</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.202</td></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">23 (65.7)</td><td align="left" colspan="1" rowspan="1">190 (42.7)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">7 (58.3)</td><td align="left" colspan="1" rowspan="1">11 (84.6)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"> ≥ 2</td><td align="left" colspan="1" rowspan="1">12 (34.3)</td><td align="left" colspan="1" rowspan="1">255 (57.3)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">5 (41.7)</td><td align="left" colspan="1" rowspan="1">2 (15.4)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Previous liver disease</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.670</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.480</td></tr><tr><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">2 (5.7)</td><td align="left" colspan="1" rowspan="1">20 (4.5)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">2 (15.4)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">33 (94.3)</td><td align="left" colspan="1" rowspan="1">425 (95.5)</td><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">12 (100.0)</td><td align="left" colspan="1" rowspan="1">11 (84.6)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Previous irAEs</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.593</td></tr><tr><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1">3 (23.1)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">11 (91.7)</td><td align="left" colspan="1" rowspan="1">10 (76.9)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Concurrent irAEs</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1">0.411</td></tr><tr><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">5 (41.7)</td><td align="left" colspan="1" rowspan="1">3 (23.1)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">7 (58.3)</td><td align="left" colspan="1" rowspan="1">10 (76.9)</td><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">The onset time of IRH, day (range)</td><td align="left" colspan="1" rowspan="1">80.0 (8.0–584.0)</td><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">68.5 (21.0–426.0)</td><td align="left" colspan="1" rowspan="1">101.0 (30.0–393.0)</td><td align="char" char="." colspan="1" rowspan="1">0.508</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean dose of steroids, mg/kg (range)</td><td align="left" colspan="1" rowspan="1">2.0 (1.0–2.0)</td><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.0 (1.0–2.0)</td><td align="left" colspan="1" rowspan="1">2.0 (1.0–2.0)</td><td align="char" char="." colspan="1" rowspan="1">0.206</td></tr><tr><td align="left" colspan="1" rowspan="1">Duration of steroids</td><td align="left" colspan="1" rowspan="1">47.0 (30.0–77.0)</td><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">37.0 (30.0–64.0)</td><td align="left" colspan="1" rowspan="1">61.5 (43.0–77.0)</td><td align="char" char="." colspan="1" rowspan="1">0.037</td></tr></tbody></table><table-wrap-foot><p>irAEs—immune-related adverse events; IRH—immune-related hepatotoxicity; Ref-IRH—steroid-refractory immune-related hepatotoxicity; Res-IRH—steroid-responsive immune-related hepatotoxicity; ICI—immune checkpoint inhibitor; PD-1—programmed cell death protein-1; CTLA-4—cytotoxic T lymphocyte-associated protein 4</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec9"><title>Comparison of clinical features between patients with IRH and non-IRH</title><p id="Par42">The patients’ clinical characteristics are summarized in (Table <xref ref-type="table" rid="Tab1">1</xref>). We first compared the clinical features of patients with and without IRH. In both groups, most patients were male, had metastatic disease, and received anti-PD-1-containing treatments. Patients with IRH were more likely to have liver metastasis (<italic toggle="yes">p</italic> = 0.019), and receive anti-PD-1 plus anti-CTLA-4 (<italic toggle="yes">p</italic> = 0.008), ICI and targeted therapy (<italic toggle="yes">p</italic> = 0.012), or first-line immunotherapy (<italic toggle="yes">p</italic> = 0.012). We also analyzed whether peripheral blood biomarkers were associated with the development of IRH. Patients with IRH had lower ALC (<italic toggle="yes">p</italic> = 0.001), lower MLR (<italic toggle="yes">p</italic> &lt; 0.001), and lower platelet counts (<italic toggle="yes">p</italic> = 0.007), and higher procalcitonin (<italic toggle="yes">p</italic> &lt; 0.001), LDH (<italic toggle="yes">p</italic> &lt; 0.001), IL-2 (<italic toggle="yes">p</italic> = 0.035), IL-6 (<italic toggle="yes">p</italic> = 0.003), and IL-10 levels (<italic toggle="yes">p</italic> &lt; 0.001) at diagnosis of irAEs compared with those with non-IRH. There was no significant difference in cancer types, absolute blood cell count, protein levels, lymphocyte count, other cytokines (IFN-γ, IL-12, and IL-17), or blood indicators between the two groups (Fig. <xref ref-type="fig" rid="Fig2">2</xref>A–D).<fig id="Fig2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Comparative analysis of blood cells, plasma proteins, and cytokines in patients with and without IRH at time of diagnosis. <bold>A</bold> Heatmap showing relative values of blood cell counts and plasma protein concentrations. <bold>B</bold> Comparison of the blood cell counts and plasma protein concentrations between patients with and without IRH. <bold>C</bold> Heatmap showing relative values of cytokines. <bold>D</bold> Comparison of the plasma concentrations of cytokines between patients with and without IRH. Unpaired t-test or Welch’s t-test. Data with error bars are shown as mean ± SEM. ns, not significant; *, <italic toggle="yes">p</italic> &lt; 0.05; **, <italic toggle="yes">p</italic> &lt; 0.01; ***, <italic toggle="yes">p</italic> &lt; 0.001; ***, <italic toggle="yes">p</italic> &lt; 0.0001. ANC: absolute neutrophil count; ALC: absolute lymphocyte count; AEC: absolute eosinophil count; MON: monocyte; PLT: platelet; ALB: albumin; LDH: lactate dihydrogen; PCT: procalcitonin; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; MLR: monocyte-to-lymphocyte ratio; ELR: eosinophil-to-lymphocyte ratio; SII: systemic immune-inflammatory index; CRP: C-reactive protein</p></caption><graphic id="MO2" orientation="portrait" position="float" xlink:href="262_2025_4287_Fig2_HTML.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p></sec><sec id="Sec10"><title>Comparison of clinical characteristics between patients with Ref-IRH and Res-IRH</title><p id="Par43">Among 13 patients with Ref-IRH, 7 underwent liver biopsy. All patients with Ref-IRH had mild to moderate bile duct injury, and 28.6% (2/7) had ductopenia. All patients had varying degrees of lobular inflammation, ranging from mild to moderate degrees, with a mixture of infiltrated inflammatory cells. Representative liver histological findings of Ref-IRH were observed in an HCC patient (Fig. <xref ref-type="media" rid="MOESM1">S1</xref>A), a gastric patient (Fig. <xref ref-type="media" rid="MOESM1">S1</xref>B), and non-small cell lung cancer patient (Fig. <xref ref-type="media" rid="MOESM1">S1</xref>C). We next compared the clinical characteristics of patients with Ref-IRH and Res-IRH. Patients with Ref-IRH were more likely to receive ICI and targeted therapy combinations (61.5 vs. 25.0%, <italic toggle="yes">p</italic> = 0.046). Hepatocellular carcinoma (HCC) patients had a greater risk of Ref-IRH than patients with non-HCC malignancies did (100% vs. 40.0%, <italic toggle="yes">p</italic> = 0.035). There was no difference between the Ref-IRH and Res-IRH groups regarding smoking status, ICI type, previous liver disease, previous irAEs, or concurrent irAEs. The onset times of Ref-IRH and Res-IRH were similar (101.0 days vs. 68.5 days, <italic toggle="yes">p</italic> = 0.508) (Table <xref ref-type="table" rid="Tab1">1</xref>). Patients with Ref-IRH had a longer duration of steroid use (61.5 days vs. 37.0 days, <italic toggle="yes">p</italic> = 0.037) compared with patients with Res-IRH, and the mean dose of steroids was comparable (2 mg/kg vs. 1.0 mg/kg, <italic toggle="yes">p</italic> = 0.206). There was no difference between the Ref-IRH and Res-IRH groups in terms of hepatic injury (<italic toggle="yes">p</italic> = 0.612) (Fig. <xref ref-type="fig" rid="Fig3">3</xref>A). In addition, Ref-IRH patients were more likely to have higher CTCAE grades (<italic toggle="yes">p</italic> = 0.044) than Res-IRH were (Fig. <xref ref-type="fig" rid="Fig3">3</xref>B). Patients with Ref-IRH had higher peak levels of TBIL (<italic toggle="yes">p</italic> = 0.003), DBIL (<italic toggle="yes">p</italic> = 0.001), and IBIL (<italic toggle="yes">p</italic> = 0.051) but not ALT (<italic toggle="yes">p</italic> = 0.225), AST (<italic toggle="yes">p</italic> = 0.469), or ALP (<italic toggle="yes">p</italic> = 0.348) (Fig. <xref ref-type="fig" rid="Fig3">3</xref>C). We also analyzed whether peripheral blood biomarkers were associated with the development of Ref-IRH. The results revealed that patients with Ref-IRH had lower platelet counts (<italic toggle="yes">p</italic> = 0.006), higher procalcitonin levels (<italic toggle="yes">p</italic> = 0.012), and higher IL-6 levels (<italic toggle="yes">p</italic> = 0.038) at diagnosis of IRH than did those with Res-IRH. There was no significant difference in absolute blood cells, proteins, lymphocytes, cytokines, or blood indicators between the two groups (Fig. <xref ref-type="fig" rid="Fig3">3</xref>D–G). Univariate logistic regression analysis indicated that high IL-6 levels (<italic toggle="yes">p</italic> = 0.019) and grade 4 disease (<italic toggle="yes">p</italic> = 0.031) can predict the development of Ref-IRH (Table <xref ref-type="table" rid="Tab2">2</xref>).<fig id="Fig3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Comparative analysis of liver injury pattern and grade, liver function, blood cells, proteins, and cytokines in patients with Ref-IRH and Res-IRH at the time of diagnosis. <bold>A</bold> Liver injury pattern. <bold>B</bold> Liver injury grade according to the CTCAE grade. <bold>C</bold> Liver function in patients with Ref-IRH and Res-IRH. <bold>D</bold> Heatmap showing relative values of blood cell counts and plasma protein concentrations. <bold>E</bold> Comparison of the blood cell counts and plasma protein concentrations between patients with Ref-IRH and Res-IRH. <bold>F</bold> Heatmap showing the relative values of cytokines. <bold>G</bold> Comparison of the plasma concentrations of cytokines between patients with Ref-IRH and Res-IRH. Data with error bars are shown as mean ± SEM. ns, not significant; *, <italic toggle="yes">p</italic> &lt; 0.05; **, <italic toggle="yes">p</italic> &lt; 0.01. ALT: alanine transaminase; AST: aspartate transaminase; TBIL: total bilirubin; DBIL: direct bilirubin; IBIL: indirect bilirubin; ALP: alkaline phosphatase</p></caption><graphic id="MO3" orientation="portrait" position="float" xlink:href="262_2025_4287_Fig3_HTML.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><table-wrap id="Tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Logistic regression analysis for risk factors of Ref-IRH</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Univariate analysis, OR (95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Sex (Male vs Female)</td><td align="char" char="–" colspan="1" rowspan="1">8.57 (0.83–89.04)</td><td align="char" char="." colspan="1" rowspan="1">0.072</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoking status (current/former vs never)</td><td align="char" char="–" colspan="1" rowspan="1">2.25 (0.44–11.52)</td><td align="char" char="." colspan="1" rowspan="1">0.330</td></tr><tr><td align="left" colspan="1" rowspan="1">IL-6 (≥ 11.32 vs &lt; 11.32), pg/ml</td><td align="char" char="–" colspan="1" rowspan="1">36.00 (1.80–718.68)</td><td align="char" char="." colspan="1" rowspan="1">0.019</td></tr><tr><td align="left" colspan="1" rowspan="1">IL-10 (≥ 5.45 vs &lt; 5.45), pg/ml</td><td align="char" char="." colspan="1" rowspan="1">6.25 (0.62–63.54)</td><td align="char" char="." colspan="1" rowspan="1">0.121</td></tr><tr><td align="left" colspan="1" rowspan="1">PLT (&lt; 181.50 vs ≥ 181.50), × 10<sup>9</sup>/L</td><td align="char" char="–" colspan="1" rowspan="1">36.00 (3.19–405.90)</td><td align="char" char="." colspan="1" rowspan="1">0.004</td></tr><tr><td align="left" colspan="1" rowspan="1">PCT (≥ 0.28 vs &lt; 0.28), × ng/ml</td><td align="char" char="–" colspan="1" rowspan="1">48.00 (2.47–932.85)</td><td align="char" char="." colspan="1" rowspan="1">0.011</td></tr><tr><td align="left" colspan="1" rowspan="1">IRH grade (G4 vs G1-3)</td><td align="char" char="–" colspan="1" rowspan="1">12.83 (1.26–130.51)</td><td align="char" char="." colspan="1" rowspan="1">0.031</td></tr><tr><td align="left" colspan="1" rowspan="1">Combination therapy (ICI + targeted therapy vs ICI + chemotherapy)</td><td align="char" char="–" colspan="1" rowspan="1">4.80 (0.86–26.79)</td><td align="char" char="." colspan="1" rowspan="1">0.074</td></tr></tbody></table><table-wrap-foot><p>IRH—immune-related hepatotoxicity; ICI—immune checkpoint inhibitor; OR—odds ratio</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Outcomes of patients with Ref-IRH</title><p id="Par44">We next compared the clinical outcomes between patients with and without IRH. The median PFS times for patients with IRH and non-IRH were 14.2 and 5.8 months, respectively (HR: 0.57, 95% CI: 0.41–0.78, <italic toggle="yes">p</italic> &lt; 0.001). The median OS times for patients with IRH and non-IRH were 27.2 and 18.5 months, respectively (HR: 0.69, 95% CI: 0.45–1.06, <italic toggle="yes">p</italic> = 0.087). The ORR with patients for Ref-IRH was comparable to that for patients with Res-IRH (38.2% vs. 20.7%, <italic toggle="yes">p</italic> = 0.029) (Fig. <xref ref-type="fig" rid="Fig4">4</xref>A–C). In addition, 10 patients with grade 1 IRH did not receive corticosteroid treatment, including 4 with the hepatocellular type, 2 with the cholestatic type, and 4 with the mixed type. The ORR was 30%. These patients received continued ICI treatment, with a median PFS of 13.8 months and median OS of 19.5 months.<fig id="Fig4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>The prognosis of patients with IRH. <bold>A</bold> Kaplan‒Meier survival curves for PFS in patients with non-IRH and those with IRH. <bold>B</bold> Kaplan‒Meier survival curves for OS in patients with non-IRH and IRH. <bold>C</bold> ORR for patients with non-IRH and IRH before the occurrence of irAEs. <bold>D</bold> Kaplan‒Meier survival curves for PFS in patients with Res-IRH and Ref-IRH. <bold>E</bold> Kaplan‒Meier survival curves for OS in patients with Res-IRH and Ref-IRH. <bold>F</bold> ORR for patients with Res-IRH and Ref-IRH before the occurrence of irAEs. <bold>G</bold> Efficacy of steroids in patients with Res-IRH. <bold>H</bold> Efficacy of steroids and immunosuppressants in patients with Ref-IRH. <bold>I</bold> Comparison of improvement rates between patients with G2 and those with G3-4 Ref-IRH. <bold>J</bold> Comparison of improvement rates between patients with G3 and those with G4 Ref-IRH. PFS: progression-free survival; OS: overall survival; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; IMs: immunosuppressants</p></caption><graphic id="MO4" orientation="portrait" position="float" xlink:href="262_2025_4287_Fig4_HTML.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p><p id="Par45">We next compared the clinical outcomes and efficacy between patients with Ref-IRH and those with Res-IRH. There was no significant difference in PFS or OS between patients with Ref-IRH and those with Res-IRH. The median PFS for patients with Ref-IRH and Res-IRH was 18.3 and 21.0 months, respectively (HR: 0.82, 95% CI: 0.30–2.19; <italic toggle="yes">p</italic> = 0.685). The median OS times for patients with Ref-IRH and Res-IRH were 28.3 and 23.3 months, respectively (HR: 1.01, 95% CI: 0.32–3.14; <italic toggle="yes">p</italic> = 0.989). The ORR for patients with Ref-IRH was comparable to that for patients with Res-IRH (50.0 vs. 30.8%, <italic toggle="yes">p</italic> = 0.428) (Fig. <xref ref-type="fig" rid="Fig4">4</xref>D–F). To alleviate the impact of immortal time bias, we used a 3-month landmark analysis in which patients who died prior to 3 months of ICI initiation or developed IRH after 3 months of ICI initiation were excluded. There was no significant in regarding PFS or OS between patients with IRH and those without IRH (Fig. <xref ref-type="media" rid="MOESM1">S2</xref>A and B), or between patients with Ref-IRH and those with Res-IRH (Fig. <xref ref-type="media" rid="MOESM1">S2</xref>C and D).</p><p id="Par46">Furthermore, we analyzed the efficacy of corticosteroids and immunosuppressive agents in patients with Res-IRH and Ref-IRH. All patients with Res-IRH improved with corticosteroid treatment, but 76.9% of patients with Ref-IRH improved with immunosuppressive agents. Salvage therapies using immunosuppressive agents for Ref-IRH were administered based on individual clinical conditions, including MMF monotherapy (<italic toggle="yes">n</italic> = 5) and MMF in combination with intravenous immunoglobulin (IVIG) and/or tacrolimus (TAC) (<italic toggle="yes">n</italic> = 8). Two patients with MMF combination treatment did not improve and received dual-plasma molecular absorption system (DPMAS) and/or anti-IL-6 receptor tocilizumab treatment, leading to a rapid resolution of transaminase elevation within 10 days (Fig. <xref ref-type="fig" rid="Fig4">4</xref>G and H<bold>; </bold>Table <xref ref-type="media" rid="MOESM1">S1</xref>). Patients with grade 2 Ref-IRH had the similar improvement rate as did those with grade 3–4 Ref-IRH (<italic toggle="yes">p</italic> = 0.569) (Fig. <xref ref-type="fig" rid="Fig4">4</xref>I). Patients with grade 3 Ref-IRH had a similar improvement rate as did those with grade 4 Ref-IRH (<italic toggle="yes">p</italic> = 0.735) (Fig. <xref ref-type="fig" rid="Fig4">4</xref>J).</p><p id="Par47">However, we also compared the recovery process between the two groups. The results revealed that patients with Ref-IRH had a longer time from the initial diagnosis of IRH to resolution to grade 1 (<italic toggle="yes">p</italic> = 0.002), from peak ALT to resolution to grade 1 (<italic toggle="yes">p</italic> = 0.007), from peak AST to resolution to grade 1 (<italic toggle="yes">p</italic> = 0.011), from peak TBIL to resolution to grade 1 (<italic toggle="yes">p</italic> = 0.048), and from the initial diagnosis of IRH to use of prednisone ≤ 20 mg/day (<italic toggle="yes">p</italic> = 0.025). The length of hospital stay was longer in the Ref-IRH group than in the Res-IRH group (14 days vs. 10 days, <italic toggle="yes">p</italic> = 0.017) (Table <xref ref-type="table" rid="Tab3">3</xref>).<table-wrap id="Tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>The courses of Res-IRH and Ref-IRH</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">irAE type</th><th align="left" colspan="1" rowspan="1">Ref-IRH</th><th align="left" colspan="1" rowspan="1">Res-IRH</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic></th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Days to resolution to G1 from</td></tr><tr><td align="left" colspan="1" rowspan="1">Diagnosis of initial IRH, median (range)</td><td align="left" colspan="1" rowspan="1">29.0 (16–48)</td><td align="left" colspan="1" rowspan="1">10.0 (6–17)</td><td align="char" char="." colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">Peak ALT, median (range)</td><td align="left" colspan="1" rowspan="1">20.0 (10–30)</td><td align="left" colspan="1" rowspan="1">7.0 (2–12)</td><td align="char" char="." colspan="1" rowspan="1">0.007</td></tr><tr><td align="left" colspan="1" rowspan="1">Peak AST, median (range)</td><td align="left" colspan="1" rowspan="1">20.0 (8–30)</td><td align="left" colspan="1" rowspan="1">7.0 (2–12)</td><td align="char" char="." colspan="1" rowspan="1">0.011</td></tr><tr><td align="left" colspan="1" rowspan="1">Peak TBIL, median (range)</td><td align="left" colspan="1" rowspan="1">11.0 (3–32)</td><td align="left" colspan="1" rowspan="1">6.5 (2–10)</td><td align="char" char="." colspan="1" rowspan="1">0.048</td></tr><tr><td align="left" colspan="1" rowspan="1">Start of IS, median (range)</td><td align="left" colspan="1" rowspan="1">26.0 (9–29)</td><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Days to PDN ≤ 20 mg/day from</td></tr><tr><td align="left" colspan="1" rowspan="1">Diagnosis of initial IRH, median (range)</td><td align="left" colspan="1" rowspan="1">45.0 (31–51)</td><td align="left" colspan="1" rowspan="1">31.0 (14–47)</td><td align="char" char="." colspan="1" rowspan="1">0.025</td></tr><tr><td align="left" colspan="1" rowspan="1">Start of IS, median (range)</td><td align="left" colspan="1" rowspan="1">32.0 (29–38)</td><td align="left" colspan="1" rowspan="1"/><td align="char" char="." colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Hospital length of stay</td><td align="left" colspan="1" rowspan="1">14.0 (9–29)</td><td align="left" colspan="1" rowspan="1">10.0 (5–14)</td><td align="char" char="." colspan="1" rowspan="1">0.017</td></tr></tbody></table><table-wrap-foot><p>IRH—immune-related hepatotoxicity; Ref-IRH—steroid-refractory IRH; Res-IRH—steroid-responsive IRH; ALT—alanine aminotransferase; AST—aspartate aminotransferase; TBIL—total bilirubin; IS—immunosuppressants; PDN—prednisone</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Discussion</title><p id="Par48">This study reported the clinical features, efficacy, and outcomes of IRH. Patients with Ref-IRH were more likely to be hepatocellular carcinoma, have higher grades of liver injury, lower platelet counts, higher procalcitonin levels, and higher IL-6 levels at diagnosis than were those with Res-IRH. High IL-6 levels act as a potential predictive factor for the development of Ref-IRH. Although the treatment efficacy and survival outcomes of patients with Ref-IRH were comparable to those with Res-IRH, patients with Ref-IRH were unlikely to quickly recover with a longer time from initial diagnosis of IRH to resolution to grade 1, from peak ALT and AST to resolution to grade 1, from diagnosis of IRH to use of prednisone ≤ 20 mg/day and had prolonged hospital length of stay.</p><p id="Par49">The frequency of Ref-IRH is unknown. Previous studies reported that the incidence of IRH was 2–25% with ICI monotherapy and 20% with dual therapy, and 0.8–2% of IRH patients in somatic tumor required immunosuppressive agents [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Here, we reported that the incidence of Ref-IRH was 2.7%, which was higher than that reported in previous studies. This may be associated with more attention given to be pathological diagnosis and treatment of irAEs in our study where 7/13 Ref-IRH patients underwent liver biopsy.</p><p id="Par50">Specific biomarkers for ICI-associated irAEs and liver injury have not yet been identified. Previous studies have indicated that liver injury is more common in HCC patients; and that HCC patients tend to have a greater risk of immune-related hepatitis than patients with non-HCC malignancies after ICI therapy, but this finding was not statistically significant [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. In our study, no difference was observed in IRH (17.1 vs. 82.9%) between HCC patients and non-HCC patients, but HCC patients had a higher risk of Ref-IRH than patients with non-HCC malignancies did (100 vs. 40.0%). It is not clear whether the “refractory” nature of liver injury is truly immune-mediated or related to hepatic decompensation in a compromised liver. Further investigations on the frequency and potential mechanisms associated with Ref-IRH are needed in HCC cohorts with large sample sizes. Furthermore, we found that patients with Ref-IRH had significantly higher PCT levels. Although high PCT is a strong marker for bacterial infection, we excluded cholangitis or sepsis in all patients including those with liver metastases or HCC. In our cohort, no patients with higher PCT levels were identified as having infection. High baseline levels of inflammatory markers and PCT are strongly predictive of poor outcomes in patients with metastatic NSCLC receiving PD-1/PD-L1 immune checkpoint blockade [<xref ref-type="bibr" rid="CR23">23</xref>]. High procalcitonin levels are even found in NSCLC patients with steroid-refractory checkpoint inhibitor pneumonitis (ALT) and aspartate aminotransferase (AST) falling below 5× the upper limit of normal (ULN) by day 7 [<xref ref-type="bibr" rid="CR24">24</xref>]. Immunotherapy may be associated with noninfectious PCT elevation.</p><p id="Par51">There is growing evidence that immunotoxicity profiles can be tied to specific cytokines that can amplify both pro- and anti-inflammatory responses [<xref ref-type="bibr" rid="CR25">25</xref>]. Baseline peripheral blood biomarkers [<xref ref-type="bibr" rid="CR26">26</xref>], cytokines [<xref ref-type="bibr" rid="CR27">27</xref>], C-reactive protein [<xref ref-type="bibr" rid="CR28">28</xref>], and early increases in CXCL9/CXCL10/CXCL11 and IFN-γ levels 1 to 2 weeks after the start of therapy are likely predictors of an increased risk of developing irAEs [<xref ref-type="bibr" rid="CR29">29</xref>]. Increased expression of IL1B, CXCL8, and CXCL2 in monocytes and TNF in macrophages was closely associated with severe irAEs according to single-cell RNA sequencing of peripheral blood mononuclear cells before treatment [<xref ref-type="bibr" rid="CR30">30</xref>]. A single toxicity score CYTOX, which integrated the expression of 11 cytokines, can be used for more objective prediction of irAEs [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par52">IL-6 is an important cytokine for the differentiation of naïve CD4<sup>+</sup> T cells into TH17 cells and plays a pivotal role in the pathogenesis of several autoimmune diseases such as rheumatoid arthritis, systemic sclerosis-associated interstitial lung diseases, and cytokine release syndrome, where the use of anti-IL-6 receptor antibodies is currently approved [<xref ref-type="bibr" rid="CR32">32</xref>]. An early increase in Th17 cytokine signatures and congruent on-treatment expansions of Th17 and Th2 effector memory T-cell populations in peripheral blood were positively associated with the development of grade ≥ 2 irAEs [<xref ref-type="bibr" rid="CR33">33</xref>]. Specifically, elevated circulating or local IL-6 was shown to be associated with the occurrence of de novo immune-related arthritis, pneumonitis, psoriasis, and other irAEs involving different organ systems [<xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR40">40</xref>]. In a murine model of live injury secondary to combined anti-CTLA-4 and anti-PDL-1 therapy, hepatocyte apoptosis, caused by the activation of the NLRP3 inflammasome and the production of proinflammatory cytokines such as IL-6, IL-1β, IL-18, and TNF-α were observed [<xref ref-type="bibr" rid="CR41">41</xref>]. In atezolizumab- and bevacizumab-treated unresectable HCC patients, the presence of fever was a significant risk factor for liver injury, and patients with preceding fever had significantly higher IL-6 levels at 1 and 3 weeks of treatment [<xref ref-type="bibr" rid="CR42">42</xref>]. Here, we focused on Ref-IRH and reported that high IL-6 levels at diagnosis were significantly associated with the development of irAEs, although this conclusion warrants prospective validation. This is the first study indicating a relationship between Ref-IRH development and elevated serum levels of IL-6. Future studies will focus on whether Ref-IRH is associated with the dynamics of IL-6 levels after treatment with ICIs and the occurrence of Ref-IRH.</p><p id="Par53">Several retrospective studies have indicated that patients who develop IRH have improved survival compared with those that do not develop IRH [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR43">43</xref>–<xref ref-type="bibr" rid="CR46">46</xref>]; however, some studies have also suggested negative or opposite results in HCC, melanoma, NSCLC, and other solid cancers [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR47">47</xref>–<xref ref-type="bibr" rid="CR51">51</xref>]. Our reports revealed a positive association between prolonged PFS and IRH. However, fatal toxic effects associated with anti-PD-1/PD-L1 therapy often include pneumonitis (35%), hepatitis (22%), and neurotoxic effects (15%) according to the Vigilyze database [<xref ref-type="bibr" rid="CR52">52</xref>]. We also reported that delayed hepatic and respiratory irAEs tended to occur more commonly in the fatal group in the FAERS database [<xref ref-type="bibr" rid="CR53">53</xref>]. Here, we did not observe significant difference in ORR, PFS, or OS between patients with Ref-IRH and those with Res-IRH, but patients with Ref-IRH had a longer time from diagnosis of IRH to resolution to low grade and longer exposure to high-dose steroids although all Ref-IRH patients were treated with immune suppressive agents. Thus, high-grade Ref-IRH is not always fatal, but a long time to resolution is needed. Furthermore, additional immunosuppressants alone or in combination are needed but not are always effective for the management of Ref-IRH [<xref ref-type="bibr" rid="CR54">54</xref>–<xref ref-type="bibr" rid="CR57">57</xref>]. Recently, neutrophil accumulation and systemic IL-6 release were identified as mechanisms associated with intestinal toxicity in response to CTLA-4 blockade, and IL-6 blockade combined with antibiotic treatment decreased intestinal damage and improved anti-CTLA-4 therapeutic efficacy in inflammation-prone mice [<xref ref-type="bibr" rid="CR58">58</xref>]. The anti-IL-6 receptor tocilizumab was effective in treating steroid-refractory high-grade immune-related cytokine release syndrome and other steroid-refractory irAEs without hindering antitumor immunity [<xref ref-type="bibr" rid="CR59">59</xref>–<xref ref-type="bibr" rid="CR61">61</xref>]. Furthermore, anti-IL-6 receptors have been successfully used in Ref-IRH and are even effective for both the treatment of irAEs and the prevention of flares of pre-existing autoimmune disorders [<xref ref-type="bibr" rid="CR62">62</xref>–<xref ref-type="bibr" rid="CR65">65</xref>]. Rechallenge with ICIs can be considered in selective Ref-IRH or checkpoint inhibitor pneumonitis patients whose prophylactic use of the anti-IL-6 receptor is under close monitoring [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. The antitumor TNF-α antibody infliximab is widely recommended as salvage therapy for immune-related colitis but never for IRH, does not result in increased hepatotoxicity and leads to a long-lasting positive response in patients with Ref-IRH [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR68">68</xref>].</p><p id="Par54">Our study has several limitations. This is a retrospective design with a small number of IRH cases. Given such a low number of events with Ref-IRH, the multivariate logistic regression model is prone to overfitting; here, we presented only the univariable association between IL-6 levels and Ref-IRH. Further studies are needed to identify whether IL-6 is an independent risk factor for the development of Ref-IRH in cohorts with large sample sizes via multivariate logistic regression analysis. In addition, this study focused on IRH regardless of cancer type, disease stage, and treatment line. Included patients were highly heterogeneous. Survival analyses should be performed in a subgroup of patients with specific cancer types, such as HCC, lung cancer, and melanoma who experienced IRH or Ref-IRH. Live biopsy was not performed in all IRH patients, which means that other reasons associated with liver injury cannot be completely ruled out. In our study, even though immunosuppressive agents were administrated to all patients with Ref-IRH, only one patient was treated with an anti-IL-6 receptor. No histological data for IL-6 is presented to confirm local upregulation of this cytokine in the liver tissue. Investigations on the possible IL-6-mediated molecular mechanisms responsible for Ref-IRH are also needed.</p><p id="Par55">In summary, the present study indicated that high IL-6 at diagnosis was a potential risk factor for the development of Ref-IRH. There was no significant difference in efficacy with immunosuppressive agents and survival outcomes between patients with Ref-IRH and Res-IRH, but much more time from the time of initial diagnosis of IRH to resolution to grade 1 and the use of immunosuppressive agents are needed for Ref-IRH.</p></sec><sec id="Sec13" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" orientation="portrait" position="float"><media orientation="portrait" position="float" xlink:href="262_2025_4287_MOESM1_ESM.docx" xmlns:xlink="http://www.w3.org/1999/xlink"><caption><p>Supplementary file1 (DOCX 651 KB)</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AJCC</term><def><p id="Par2">The American joint committee on cancer</p></def></def-item><def-item><term>BLR</term><def><p id="Par3">Basophil-to-lymphocyte ratio</p></def></def-item><def-item><term>BMI</term><def><p id="Par4">Body mass index</p></def></def-item><def-item><term>CTLA-4</term><def><p id="Par5">Cytotoxic T lymphocyte-associated antigen-4</p></def></def-item><def-item><term>CR</term><def><p id="Par6">Complete response</p></def></def-item><def-item><term>DCR</term><def><p id="Par7">Disease control rate</p></def></def-item><def-item><term>ECOG</term><def><p id="Par8">Eastern cooperative oncology group </p></def></def-item><def-item><term>ELISA</term><def><p id="Par9">Enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>HCC</term><def><p id="Par10">Hepatocellular carcinoma</p></def></def-item><def-item><term>ICIs</term><def><p id="Par11">Immune checkpoint inhibitors</p></def></def-item><def-item><term>IFN-γ</term><def><p id="Par12">Interferon-γ</p></def></def-item><def-item><term>IL</term><def><p id="Par13">Interleukin</p></def></def-item><def-item><term>irAEs</term><def><p id="Par14">Immune-related adverse events</p></def></def-item><def-item><term>IRH</term><def><p id="Par15">Immune-related hepatotoxicity</p></def></def-item><def-item><term>MLR</term><def><p id="Par16">Monocyte-to-lymphocyte ratio</p></def></def-item><def-item><term>NLR</term><def><p id="Par17">Neutrophil-to-lymphocyte ratio</p></def></def-item><def-item><term>NSCLC</term><def><p id="Par18">Non-small cell lung cancer</p></def></def-item><def-item><term>ORR</term><def><p id="Par19">Objective response rate</p></def></def-item><def-item><term>OS</term><def><p id="Par20">Overall survival</p></def></def-item><def-item><term>PD</term><def><p id="Par21">Progressive disease</p></def></def-item><def-item><term>PD-1</term><def><p id="Par22">Programmed cell death protein-1</p></def></def-item><def-item><term>PD-L1</term><def><p id="Par23">Programmed cell death ligand-1</p></def></def-item><def-item><term>PFS</term><def><p id="Par24">Progression-free survival</p></def></def-item><def-item><term>PLR</term><def><p id="Par25">Platelet-to-lymphocyte ratio</p></def></def-item><def-item><term>PR</term><def><p id="Par26">Partial response</p></def></def-item><def-item><term>PS</term><def><p id="Par27">Performance status</p></def></def-item><def-item><term>RECIST</term><def><p id="Par28">Response evaluation criteria in solid tumors</p></def></def-item><def-item><term>SD</term><def><p id="Par29">Stable disease</p></def></def-item><def-item><term>SII</term><def><p id="Par30">Systemic immunity-inflammation index</p></def></def-item><def-item><term>Ref-IRH</term><def><p id="Par31">Steroid-refractory IRH</p></def></def-item><def-item><term>Res-IRH</term><def><p id="Par32">Steroid-responsive IRH</p></def></def-item><def-item><term>TNF-α</term><def><p id="Par33">Tumor necrosis factor-α</p></def></def-item><def-item><term>TNM</term><def><p id="Par34">Tumor node metastasis</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Songlin Liu, Yuekai Zhang, and Yaping Guan have contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors acknowledge all participating patients and their families. We are also thankful to the staff of all the institutions involved in this study.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>JW and SL were involved in the study design and concept. SL, YZ, and YG drafted the manuscript. SL and YZ performed the statistical analysis. SL and YG conducted the experiments. SL, HX, YD, JC, and QX provided patient samples and clinical data. SL, YZ, YG, HX, YD, JC, and QX revised the manuscript for critical intellectual content. All the authors read and approved the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was partially supported by the National Natural Science Foundation of China (Grant No. 81572875), Shandong Provincial Natural Science Foundation (Grant No. ZR2021MH291), Cultivating Fund of the First Affiliated Hospital of Shandong First Medical University (QYPY2022NSFC0613), CSCO-MSD Cancer Research Foundation (Grant No. Y-MSD2020-0350), CSCO-PILOT Cancer Research Foundation (Grant No. Y-2019AZMS-0440), and Wu Jieping Medical Foundation for Clinical Scientific Research (Grant No. 320.6750.2020–12-16). The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par56">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethics approval</title><p id="Par57">This study was approved by the Research Ethics Committee of the First Affiliated Hospital of Shandong First Medical University (NO: YXLL-KY-2022–059).</p></notes><notes id="FPar3"><title>Consent to participate</title><p id="Par58">Owing to the retrospective design of the study, the Research Ethics Committee of the First Affiliated Hospital of Shandong First Medical University granted a waiver of the requirement for informed consent. We confirmed that all methods were performed in accordance with the relevant guidelines.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schreiber</surname><given-names>RD</given-names></name><name name-style="western"><surname>Old</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><article-title>Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion</article-title><source>Science</source><year>2011</year><volume>331</volume><fpage>1565</fpage><lpage>1570</lpage><pub-id pub-id-type="doi">10.1126/science.1203486</pub-id><pub-id pub-id-type="pmid">21436444</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570. 10.1126/science.1203486<pub-id pub-id-type="pmid">21436444</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1126/science.1203486</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Postow</surname><given-names>MA</given-names></name><name name-style="western"><surname>Sidlow</surname><given-names>R</given-names></name><name name-style="western"><surname>Hellmann</surname><given-names>MD</given-names></name></person-group><article-title>Immune-related adverse events associated with immune checkpoint blockade</article-title><source>N Engl J Med</source><year>2018</year><volume>378</volume><fpage>158</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1703481</pub-id><pub-id pub-id-type="pmid">29320654</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168. 10.1056/NEJMra1703481<pub-id pub-id-type="pmid">29320654</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1056/NEJMra1703481</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H</given-names></name><etal/></person-group><article-title>Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors</article-title><source>BMC Cancer</source><year>2025</year><volume>25</volume><fpage>139</fpage><pub-id pub-id-type="doi">10.1186/s12885-025-13566-6</pub-id><pub-id pub-id-type="pmid">39856626</pub-id><pub-id pub-id-type="pmcid">PMC11761211</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Han X, Chen Y, Xie H et al (2025) Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors. BMC Cancer 25:139. 10.1186/s12885-025-13566-6<pub-id pub-id-type="pmid">39856626</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/s12885-025-13566-6</pub-id><pub-id pub-id-type="pmcid">PMC11761211</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Martin</surname><given-names>E</given-names></name><name name-style="western"><surname>Michot</surname><given-names>JM</given-names></name><name name-style="western"><surname>Papouin</surname><given-names>B</given-names></name><etal/></person-group><article-title>Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors</article-title><source>J Hepatol</source><year>2018</year><volume>68</volume><fpage>1181</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.01.033</pub-id><pub-id pub-id-type="pmid">29427729</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">De Martin E, Michot JM, Papouin B et al (2018) Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 68:1181–1190. 10.1016/j.jhep.2018.01.033<pub-id pub-id-type="pmid">29427729</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2018.01.033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Martin</surname><given-names>E</given-names></name><name name-style="western"><surname>Michot</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rosmorduc</surname><given-names>O</given-names></name><name name-style="western"><surname>Guettier</surname><given-names>C</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>D</given-names></name></person-group><article-title>Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors</article-title><source>JHEP Rep</source><year>2020</year><volume>2</volume><fpage>100170</fpage><pub-id pub-id-type="doi">10.1016/j.jhepr.2020.100170</pub-id><pub-id pub-id-type="pmid">33205034</pub-id><pub-id pub-id-type="pmcid">PMC7648167</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">De Martin E, Michot JM, Rosmorduc O, Guettier C, Samuel D (2020) Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep 2:100170. 10.1016/j.jhepr.2020.100170<pub-id pub-id-type="pmid">33205034</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhepr.2020.100170</pub-id><pub-id pub-id-type="pmcid">PMC7648167</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Naidoo</surname><given-names>J</given-names></name><name name-style="western"><surname>Santomasso</surname><given-names>BD</given-names></name><name name-style="western"><surname>Lacchetti</surname><given-names>C</given-names></name><name name-style="western"><surname>Adkins</surname><given-names>S</given-names></name><name name-style="western"><surname>Anadkat</surname><given-names>M</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>MB</given-names></name><name name-style="western"><surname>Brassil</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Caterino</surname><given-names>JM</given-names></name><name name-style="western"><surname>Chau</surname><given-names>I</given-names></name><etal/></person-group><article-title>Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update</article-title><source>J Clin Oncol</source><year>2021</year><volume>39</volume><fpage>4073</fpage><lpage>4126</lpage><pub-id pub-id-type="doi">10.1200/JCO.21.01440</pub-id><pub-id pub-id-type="pmid">34724392</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39:4073–4126. 10.1200/JCO.21.01440<pub-id pub-id-type="pmid">34724392</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1200/JCO.21.01440</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brahmer</surname><given-names>JR</given-names></name><name name-style="western"><surname>Abu-Sbeih</surname><given-names>H</given-names></name><name name-style="western"><surname>Ascierto</surname><given-names>PA</given-names></name><name name-style="western"><surname>Brufsky</surname><given-names>J</given-names></name><name name-style="western"><surname>Cappelli</surname><given-names>LC</given-names></name><name name-style="western"><surname>Cortazar</surname><given-names>FB</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>DE</given-names></name><name name-style="western"><surname>Hamad</surname><given-names>L</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>E</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>DB</given-names></name><etal/></person-group><article-title>Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events</article-title><source>J Immunother Cancer</source><year>2021</year><volume>9</volume><fpage>e002435</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-002435</pub-id><pub-id pub-id-type="pmid">34172516</pub-id><pub-id pub-id-type="pmcid">PMC8237720</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB et al (2021) Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9:e002435. 10.1136/jitc-2021-002435<pub-id pub-id-type="pmid">34172516</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/jitc-2021-002435</pub-id><pub-id pub-id-type="pmcid">PMC8237720</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Brahmer</surname><given-names>J</given-names></name></person-group><article-title>NCCN guidelines® insights: management of immunotherapy-related toxicities, version 2.2024</article-title><source>J Natl Compr Canc Netw</source><year>2024</year><volume>22</volume><issue>9</issue><fpage>582</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2024.0057</pub-id><pub-id pub-id-type="pmid">39536465</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Thompson JA, Schneider BJ, Brahmer J (2024) NCCN guidelines® insights: management of immunotherapy-related toxicities, version 2.2024. J Natl Compr Canc Netw 22(9):582–592. 10.6004/jnccn.2024.0057<pub-id pub-id-type="pmid">39536465</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.6004/jnccn.2024.0057</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>V</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>T</given-names></name><name name-style="western"><surname>Payne</surname><given-names>M</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>MR</given-names></name><name name-style="western"><surname>Collier</surname><given-names>JD</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>A</given-names></name><name name-style="western"><surname>Klenerman</surname><given-names>P</given-names></name><name name-style="western"><surname>Brain</surname><given-names>O</given-names></name><name name-style="western"><surname>Cobbold</surname><given-names>JF</given-names></name></person-group><article-title>Immunotherapy-related hepatitis: real-world experience from a tertiary centre</article-title><source>Frontline Gastroenterol</source><year>2019</year><volume>10</volume><fpage>364</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1136/flgastro-2018-101146</pub-id><pub-id pub-id-type="pmid">31656561</pub-id><pub-id pub-id-type="pmcid">PMC6788136</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Cheung V, Gupta T, Payne M, Middleton MR, Collier JD, Simmons A, Klenerman P, Brain O, Cobbold JF (2019) Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterol 10:364–371. 10.1136/flgastro-2018-101146<pub-id pub-id-type="pmid">31656561</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/flgastro-2018-101146</pub-id><pub-id pub-id-type="pmcid">PMC6788136</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patrinely</surname><given-names>JR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>McGuigan</surname><given-names>B</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>S</given-names></name><etal/></person-group><article-title>A multicenter characterization of hepatitis associated with immune checkpoint inhibitors</article-title><source>Oncoimmunology</source><year>2021</year><volume>10</volume><fpage>1875639</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2021.1875639</pub-id><pub-id pub-id-type="pmid">33628621</pub-id><pub-id pub-id-type="pmcid">PMC7889227</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Patrinely JR Jr, McGuigan B, Chandra S et al (2021) A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology 10:1875639. 10.1080/2162402X.2021.1875639<pub-id pub-id-type="pmid">33628621</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/2162402X.2021.1875639</pub-id><pub-id pub-id-type="pmcid">PMC7889227</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>SY</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Steroid-refractory immune checkpoint inhibitor (ICI) hepatitis and ICI rechallenge: a systematic review and meta-analysis</article-title><source>Hepatol Commun</source><year>2024</year><volume>8</volume><fpage>e0525</fpage><pub-id pub-id-type="doi">10.1097/HC9.0000000000000525</pub-id><pub-id pub-id-type="pmid">39298568</pub-id><pub-id pub-id-type="pmcid">PMC11412713</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Hwang SY, Hsieh P, Zhang W et al (2024) Steroid-refractory immune checkpoint inhibitor (ICI) hepatitis and ICI rechallenge: a systematic review and meta-analysis. Hepatol Commun 8:e0525. 10.1097/HC9.0000000000000525<pub-id pub-id-type="pmid">39298568</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/HC9.0000000000000525</pub-id><pub-id pub-id-type="pmcid">PMC11412713</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McIlwaine</surname><given-names>S</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>A</given-names></name><name name-style="western"><surname>Stratton</surname><given-names>L</given-names></name><name name-style="western"><surname>Oladipo</surname><given-names>B</given-names></name><name name-style="western"><surname>Cash</surname><given-names>J</given-names></name><name name-style="western"><surname>Carser</surname><given-names>J</given-names></name><name name-style="western"><surname>Braniff</surname><given-names>C</given-names></name></person-group><article-title>The use of tacrolimus in the management of checkpoint inhibitor immunotherapy-induced hepatitis</article-title><source>J R Coll Phys Edinb</source><year>2022</year><volume>52</volume><fpage>20</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1177/14782715221088911</pub-id><pub-id pub-id-type="pmid">36146973</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">McIlwaine S, Cullen A, Stratton L, Oladipo B, Cash J, Carser J, Braniff C (2022) The use of tacrolimus in the management of checkpoint inhibitor immunotherapy-induced hepatitis. J R Coll Phys Edinb 52:20–23. 10.1177/14782715221088911<pub-id assigning-authority="pmc" pub-id-type="doi">10.1177/14782715221088911</pub-id><pub-id pub-id-type="pmid">36146973</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burri</surname><given-names>E</given-names></name><name name-style="western"><surname>Mangana</surname><given-names>J</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>PF</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>A</given-names></name><name name-style="western"><surname>Weber</surname><given-names>A</given-names></name><name name-style="western"><surname>Dummer</surname><given-names>R</given-names></name><name name-style="western"><surname>Ramelyte</surname><given-names>E</given-names></name></person-group><article-title>Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids</article-title><source>J Immunother Cancer</source><year>2024</year><volume>12</volume><fpage>e008074</fpage><pub-id pub-id-type="doi">10.1136/jitc-2023-008074</pub-id><pub-id pub-id-type="pmid">38969522</pub-id><pub-id pub-id-type="pmcid">PMC11227818</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Burri E, Mangana J, Cheng PF, Schneider A, Weber A, Dummer R, Ramelyte E (2024) Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids. J Immunother Cancer 12:e008074. 10.1136/jitc-2023-008074<pub-id pub-id-type="pmid">38969522</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/jitc-2023-008074</pub-id><pub-id pub-id-type="pmcid">PMC11227818</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tew</surname><given-names>A</given-names></name><name name-style="western"><surname>Khoja</surname><given-names>L</given-names></name><name name-style="western"><surname>Pallan</surname><given-names>L</given-names></name><name name-style="western"><surname>Steven</surname><given-names>N</given-names></name></person-group><article-title>Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series</article-title><source>J Oncol Pharm Pract</source><year>2023</year><volume>29</volume><fpage>1163</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1177/10781552221103548</pub-id><pub-id pub-id-type="pmid">35607278</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Tew A, Khoja L, Pallan L, Steven N (2023) Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series. J Oncol Pharm Pract 29:1163–1171. 10.1177/10781552221103548<pub-id pub-id-type="pmid">35607278</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1177/10781552221103548</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGuire</surname><given-names>HM</given-names></name><name name-style="western"><surname>Shklovskaya</surname><given-names>E</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>J</given-names></name></person-group><article-title>Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report</article-title><source>Cancer Immunol Immunother</source><year>2018</year><volume>67</volume><fpage>563</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1007/s00262-017-2107-7</pub-id><pub-id pub-id-type="pmid">29289977</pub-id><pub-id pub-id-type="pmcid">PMC5860100</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">McGuire HM, Shklovskaya E, Edwards J (2018) Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunol Immunother 67:563–573. 10.1007/s00262-017-2107-7<pub-id pub-id-type="pmid">29289977</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00262-017-2107-7</pub-id><pub-id pub-id-type="pmcid">PMC5860100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ziogas</surname><given-names>DC</given-names></name><name name-style="western"><surname>Gkoufa</surname><given-names>A</given-names></name><name name-style="western"><surname>Cholongitas</surname><given-names>E</given-names></name><name name-style="western"><surname>Diamantopoulos</surname><given-names>P</given-names></name><name name-style="western"><surname>Anastasopoulou</surname><given-names>A</given-names></name><name name-style="western"><surname>Ascierto</surname><given-names>PA</given-names></name><name name-style="western"><surname>Gogas</surname><given-names>H</given-names></name></person-group><article-title>When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report</article-title><source>J Immunother Cancer</source><year>2020</year><volume>8</volume><fpage>e001322</fpage><pub-id pub-id-type="doi">10.1136/jitc-2020-001322</pub-id><pub-id pub-id-type="pmid">33144335</pub-id><pub-id pub-id-type="pmcid">PMC7607607</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Ziogas DC, Gkoufa A, Cholongitas E, Diamantopoulos P, Anastasopoulou A, Ascierto PA, Gogas H (2020) When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. J Immunother Cancer 8:e001322. 10.1136/jitc-2020-001322<pub-id pub-id-type="pmid">33144335</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/jitc-2020-001322</pub-id><pub-id pub-id-type="pmcid">PMC7607607</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alouani</surname><given-names>E</given-names></name><name name-style="western"><surname>Laparra</surname><given-names>A</given-names></name><name name-style="western"><surname>Perret</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology</article-title><source>Eur J Cancer</source><year>2023</year><volume>193</volume><fpage>113313</fpage><pub-id pub-id-type="doi">10.1016/j.ejca.2023.113313</pub-id><pub-id pub-id-type="pmid">37748398</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Alouani E, Laparra A, Perret A et al (2023) Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology. Eur J Cancer 193:113313. 10.1016/j.ejca.2023.113313<pub-id pub-id-type="pmid">37748398</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.ejca.2023.113313</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zarrabi</surname><given-names>M</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>C</given-names></name><name name-style="western"><surname>French</surname><given-names>SW</given-names></name><name name-style="western"><surname>Federman</surname><given-names>N</given-names></name><name name-style="western"><surname>Nowicki</surname><given-names>TS</given-names></name></person-group><article-title>Successful treatment of severe immune checkpoint inhibitor associated autoimmune hepatitis with basiliximab: a case report</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1156746</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1156746</pub-id><pub-id pub-id-type="pmid">37325672</pub-id><pub-id pub-id-type="pmcid">PMC10262312</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Zarrabi M, Hamilton C, French SW, Federman N, Nowicki TS (2023) Successful treatment of severe immune checkpoint inhibitor associated autoimmune hepatitis with basiliximab: a case report. Front Immunol 14:1156746. 10.3389/fimmu.2023.1156746<pub-id pub-id-type="pmid">37325672</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fimmu.2023.1156746</pub-id><pub-id pub-id-type="pmcid">PMC10262312</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>M</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R</given-names></name><name name-style="western"><surname>Butler</surname><given-names>M</given-names></name></person-group><article-title>Checkpoint inhibitor hepatotoxicity: pathogenesis and management</article-title><source>Hepatology</source><year>2024</year><volume>79</volume><fpage>198</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1097/HEP.0000000000000045</pub-id><pub-id pub-id-type="pmid">36633259</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Cunningham M, Gupta R, Butler M (2024) Checkpoint inhibitor hepatotoxicity: pathogenesis and management. Hepatology 79:198–212. 10.1097/HEP.0000000000000045<pub-id pub-id-type="pmid">36633259</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/HEP.0000000000000045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biewenga</surname><given-names>M</given-names></name><name name-style="western"><surname>van der Kooij</surname><given-names>MK</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>MWJM</given-names></name><etal/></person-group><article-title>Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients</article-title><source>Hepatol Int</source><year>2021</year><volume>15</volume><fpage>510</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1007/s12072-021-10151-4</pub-id><pub-id pub-id-type="pmid">33634373</pub-id><pub-id pub-id-type="pmcid">PMC8144142</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Biewenga M, van der Kooij MK, Wouters MWJM et al (2021) Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. Hepatol Int 15:510–519. 10.1007/s12072-021-10151-4<pub-id pub-id-type="pmid">33634373</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s12072-021-10151-4</pub-id><pub-id pub-id-type="pmcid">PMC8144142</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name></person-group><article-title>The higher incidence of liver injury in HCC patients compared to other malignancies during immune-checkpoint inhibitor therapy is primarily due to tumor progression</article-title><source>Ther Clin Risk Manag</source><year>2025</year><volume>25</volume><issue>21</issue><fpage>963</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.2147/TCRM.S514868</pub-id><pub-id pub-id-type="pmcid">PMC12206408</pub-id><pub-id pub-id-type="pmid">40584026</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Wang Y, Liu L, Zhao M, Chen W, Chen Y, Zhao X (2025) The higher incidence of liver injury in HCC patients compared to other malignancies during immune-checkpoint inhibitor therapy is primarily due to tumor progression. Ther Clin Risk Manag 25(21):963–974. 10.2147/TCRM.S514868<pub-id assigning-authority="pmc" pub-id-type="doi">10.2147/TCRM.S514868</pub-id><pub-id pub-id-type="pmcid">PMC12206408</pub-id><pub-id pub-id-type="pmid">40584026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>YP</given-names></name><name name-style="western"><surname>Lee</surname><given-names>PC</given-names></name><name name-style="western"><surname>Chang</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Hepatic events during immune checkpoint inhibitor treatment between liver and non-liver malignancies in hepatitis B endemic areas</article-title><source>Aliment Pharmacol Ther</source><year>2025</year><volume>61</volume><fpage>501</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1111/apt.18403</pub-id><pub-id pub-id-type="pmid">39582238</pub-id><pub-id pub-id-type="pmcid">PMC11707645</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Hung YP, Lee PC, Chang YH et al (2025) Hepatic events during immune checkpoint inhibitor treatment between liver and non-liver malignancies in hepatitis B endemic areas. Aliment Pharmacol Ther 61:501–512. 10.1111/apt.18403<pub-id pub-id-type="pmid">39582238</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/apt.18403</pub-id><pub-id pub-id-type="pmcid">PMC11707645</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nardone</surname><given-names>V</given-names></name><name name-style="western"><surname>Giannicola</surname><given-names>R</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>G</given-names></name><etal/></person-group><article-title>Inflammatory markers and procalcitonin predict the outcome of metastatic non-small-cell-lung-cancer patients receiving PD-1/PD-L1 immune-checkpoint blockade</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>684110</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.684110</pub-id><pub-id pub-id-type="pmid">34195086</pub-id><pub-id pub-id-type="pmcid">PMC8236817</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Nardone V, Giannicola R, Bianco G et al (2021) Inflammatory markers and procalcitonin predict the outcome of metastatic non-small-cell-lung-cancer patients receiving PD-1/PD-L1 immune-checkpoint blockade. Front Oncol 11:684110. 10.3389/fonc.2021.684110<pub-id pub-id-type="pmid">34195086</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fonc.2021.684110</pub-id><pub-id pub-id-type="pmcid">PMC8236817</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jia</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H</given-names></name></person-group><article-title>Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis</article-title><source>J Immunother Cancer</source><year>2023</year><volume>11</volume><fpage>e006982</fpage><pub-id pub-id-type="doi">10.1136/jitc-2023-006982</pub-id><pub-id pub-id-type="pmid">37290926</pub-id><pub-id pub-id-type="pmcid">PMC10254972</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Li Y, Jia X, Zhang Y, Du Y, Chang Y, Shen Y, Mao Z, Liu M, Sun H, Guo H (2023) Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis. J Immunother Cancer 11:e006982. 10.1136/jitc-2023-006982<pub-id pub-id-type="pmid">37290926</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/jitc-2023-006982</pub-id><pub-id pub-id-type="pmcid">PMC10254972</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>JH</given-names></name><name name-style="western"><surname>Bluestone</surname><given-names>JA</given-names></name><name name-style="western"><surname>Young</surname><given-names>A</given-names></name></person-group><article-title>Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines</article-title><source>Trends Immunol</source><year>2021</year><volume>42</volume><fpage>293</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.it.2021.02.006</pub-id><pub-id pub-id-type="pmid">33714688</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Kang JH, Bluestone JA, Young A (2021) Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines. Trends Immunol 42:293–311. 10.1016/j.it.2021.02.006<pub-id pub-id-type="pmid">33714688</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.it.2021.02.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavan</surname><given-names>A</given-names></name><name name-style="western"><surname>Calvetti</surname><given-names>L</given-names></name><name name-style="western"><surname>Dal Maso</surname><given-names>A</given-names></name><name name-style="western"><surname>Attili</surname><given-names>I</given-names></name><name name-style="western"><surname>Del Bianco</surname><given-names>P</given-names></name><name name-style="western"><surname>Pasello</surname><given-names>G</given-names></name><name name-style="western"><surname>Guarneri</surname><given-names>V</given-names></name><name name-style="western"><surname>Aprile</surname><given-names>G</given-names></name><name name-style="western"><surname>Conte</surname><given-names>P</given-names></name><name name-style="western"><surname>Bonanno</surname><given-names>L</given-names></name></person-group><article-title>Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors</article-title><source>Oncologist</source><year>2019</year><volume>24</volume><fpage>1128</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2018-0563</pub-id><pub-id pub-id-type="pmid">31015312</pub-id><pub-id pub-id-type="pmcid">PMC6693718</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L (2019) Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Oncologist 24:1128–1136. 10.1634/theoncologist.2018-0563<pub-id pub-id-type="pmid">31015312</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1634/theoncologist.2018-0563</pub-id><pub-id pub-id-type="pmcid">PMC6693718</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farooqi</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Öjlert</surname><given-names>ÅK</given-names></name><name name-style="western"><surname>Thunold</surname><given-names>S</given-names></name><name name-style="western"><surname>Juul</surname><given-names>HV</given-names></name><name name-style="western"><surname>Bjaanæs</surname><given-names>MM</given-names></name><name name-style="western"><surname>Horndalsveen</surname><given-names>H</given-names></name><name name-style="western"><surname>Nymoen</surname><given-names>HMG</given-names></name><name name-style="western"><surname>Helland</surname><given-names>Å</given-names></name><name name-style="western"><surname>Haakensen</surname><given-names>VD</given-names></name></person-group><article-title>Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma</article-title><source>Front Immunol</source><year>2024</year><volume>15</volume><fpage>1480183</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2024.1480183</pub-id><pub-id pub-id-type="pmid">39687621</pub-id><pub-id pub-id-type="pmcid">PMC11647018</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Farooqi SJ, Zhao Z, Öjlert ÅK, Thunold S, Juul HV, Bjaanæs MM, Horndalsveen H, Nymoen HMG, Helland Å, Haakensen VD (2024) Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma. Front Immunol 15:1480183. 10.3389/fimmu.2024.1480183<pub-id pub-id-type="pmid">39687621</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fimmu.2024.1480183</pub-id><pub-id pub-id-type="pmcid">PMC11647018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abolhassani</surname><given-names>AR</given-names></name><name name-style="western"><surname>Schuler</surname><given-names>G</given-names></name><name name-style="western"><surname>Kirchberger</surname><given-names>MC</given-names></name><name name-style="western"><surname>Heinzerling</surname><given-names>L</given-names></name></person-group><article-title>C-reactive protein as an early marker of immune-related adverse events</article-title><source>J Cancer Res Clin Oncol</source><year>2019</year><volume>145</volume><fpage>2625</fpage><lpage>2631</lpage><pub-id pub-id-type="doi">10.1007/s00432-019-03002-1</pub-id><pub-id pub-id-type="pmid">31492984</pub-id><pub-id pub-id-type="pmcid">PMC11810282</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Abolhassani AR, Schuler G, Kirchberger MC, Heinzerling L (2019) C-reactive protein as an early marker of immune-related adverse events. J Cancer Res Clin Oncol 145:2625–2631. 10.1007/s00432-019-03002-1<pub-id pub-id-type="pmid">31492984</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00432-019-03002-1</pub-id><pub-id pub-id-type="pmcid">PMC11810282</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nuñez</surname><given-names>NG</given-names></name><name name-style="western"><surname>Berner</surname><given-names>F</given-names></name><name name-style="western"><surname>Friebel</surname><given-names>E</given-names></name><etal/></person-group><article-title>Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors</article-title><source>Med</source><year>2023</year><volume>4</volume><fpage>113</fpage><lpage>129.e7</lpage><pub-id pub-id-type="doi">10.1016/j.medj.2022.12.007</pub-id><pub-id pub-id-type="pmid">36693381</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Nuñez NG, Berner F, Friebel E et al (2023) Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med 4:113-129.e7. 10.1016/j.medj.2022.12.007<pub-id pub-id-type="pmid">36693381</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.medj.2022.12.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>SI</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JE</given-names></name><name name-style="western"><surname>Chung</surname><given-names>C</given-names></name><name name-style="western"><surname>Kang</surname><given-names>YE</given-names></name><name name-style="western"><surname>Kang</surname><given-names>DH</given-names></name><name name-style="western"><surname>Park</surname><given-names>J</given-names></name></person-group><article-title>Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC</article-title><source>J Immunother Cancer</source><year>2025</year><volume>13</volume><fpage>e011636</fpage><pub-id pub-id-type="doi">10.1136/jitc-2025-011636</pub-id><pub-id pub-id-type="pmid">40404203</pub-id><pub-id pub-id-type="pmcid">PMC12097017</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Shin SI, Sun P, Lee JE, Chung C, Kang YE, Kang DH, Park J (2025) Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC. J Immunother Cancer 13:e011636. 10.1136/jitc-2025-011636<pub-id pub-id-type="pmid">40404203</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/jitc-2025-011636</pub-id><pub-id pub-id-type="pmcid">PMC12097017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>SY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Gide</surname><given-names>TN</given-names></name><etal/></person-group><article-title>Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy</article-title><source>Clin Cancer Res</source><year>2019</year><volume>25</volume><issue>5</issue><fpage>1557</fpage><lpage>1563</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2795</pub-id><pub-id pub-id-type="pmid">30409824</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Lim SY, Lee JH, Gide TN et al (2019) Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clin Cancer Res 25(5):1557–1563. 10.1158/1078-0432.CCR-18-2795<pub-id pub-id-type="pmid">30409824</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1158/1078-0432.CCR-18-2795</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diehl</surname><given-names>S</given-names></name><name name-style="western"><surname>Rincón</surname><given-names>M</given-names></name></person-group><article-title>The two faces of IL-6 on Th1/Th2 differentiation</article-title><source>Mol Immunol</source><year>2002</year><volume>39</volume><fpage>531</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1016/s0161-5890(02)00210-9</pub-id><pub-id pub-id-type="pmid">12431386</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Diehl S, Rincón M (2002) The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 39:531–536. 10.1016/s0161-5890(02)00210-9<pub-id pub-id-type="pmid">12431386</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/s0161-5890(02)00210-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kao</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Charmsaz</surname><given-names>S</given-names></name><name name-style="western"><surname>Alden</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures</article-title><source>J Clin Invest</source><year>2024</year><volume>134</volume><fpage>e176567</fpage><pub-id pub-id-type="doi">10.1172/JCI176567</pub-id><pub-id pub-id-type="pmid">39403935</pub-id><pub-id pub-id-type="pmcid">PMC11473156</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Kao CJ, Charmsaz S, Alden SL et al (2024) Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures. J Clin Invest 134:e176567. 10.1172/JCI176567<pub-id pub-id-type="pmid">39403935</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1172/JCI176567</pub-id><pub-id pub-id-type="pmcid">PMC11473156</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kowalski</surname><given-names>B</given-names></name><name name-style="western"><surname>Valaperti</surname><given-names>A</given-names></name><name name-style="western"><surname>Bezel</surname><given-names>P</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>UC</given-names></name><name name-style="western"><surname>Scholtze</surname><given-names>D</given-names></name><name name-style="western"><surname>Wieser</surname><given-names>S</given-names></name><name name-style="western"><surname>Vonow-Eisenring</surname><given-names>M</given-names></name><name name-style="western"><surname>Widmer</surname><given-names>A</given-names></name><name name-style="western"><surname>Kohler</surname><given-names>M</given-names></name><name name-style="western"><surname>Franzen</surname><given-names>D</given-names></name></person-group><article-title>Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study</article-title><source>J Cancer Res Clin Oncol</source><year>2022</year><volume>2022</volume><fpage>1711</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1007/s00432-021-03750-z</pub-id><pub-id pub-id-type="pmcid">PMC9189083</pub-id><pub-id pub-id-type="pmid">34347128</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Kowalski B, Valaperti A, Bezel P, Steiner UC, Scholtze D, Wieser S, Vonow-Eisenring M, Widmer A, Kohler M, Franzen D (2022) Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study. J Cancer Res Clin Oncol 2022:1711–1720. 10.1007/s00432-021-03750-z<pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00432-021-03750-z</pub-id><pub-id pub-id-type="pmcid">PMC9189083</pub-id><pub-id pub-id-type="pmid">34347128</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>R</given-names></name><name name-style="western"><surname>Okiyama</surname><given-names>N</given-names></name><name name-style="western"><surname>Okune</surname><given-names>M</given-names></name><etal/></person-group><article-title>Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity</article-title><source>J Dermatol Sci</source><year>2017</year><volume>86</volume><fpage>71</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2016.12.019</pub-id><pub-id pub-id-type="pmid">28069323</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Tanaka R, Okiyama N, Okune M et al (2017) Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity. J Dermatol Sci 86:71–73. 10.1016/j.jdermsci.2016.12.019<pub-id pub-id-type="pmid">28069323</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jdermsci.2016.12.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>Y</given-names></name><name name-style="western"><surname>Asano</surname><given-names>T</given-names></name><etal/></person-group><article-title>Association between inflammatory cytokines and immune-checkpoint molecule in rheumatoid arthritis</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><fpage>e0260254</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0260254</pub-id><pub-id pub-id-type="pmid">34793561</pub-id><pub-id pub-id-type="pmcid">PMC8601500</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Matsumoto H, Fujita Y, Asano T et al (2021) Association between inflammatory cytokines and immune-checkpoint molecule in rheumatoid arthritis. PLoS ONE 16:e0260254. 10.1371/journal.pone.0260254<pub-id pub-id-type="pmid">34793561</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1371/journal.pone.0260254</pub-id><pub-id pub-id-type="pmcid">PMC8601500</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tan</surname><given-names>K</given-names></name><name name-style="western"><surname>Cui</surname><given-names>H</given-names></name></person-group><article-title>Changes of IL-6 and IFN-γ before and after the adverse events related to immune checkpoint inhibitors: a retrospective study</article-title><source>Medicine (Baltimore)</source><year>2022</year><volume>101</volume><issue>46</issue><fpage>e31761</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000031761</pub-id><pub-id pub-id-type="pmid">36401365</pub-id><pub-id pub-id-type="pmcid">PMC9678612</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Zhang X, Lu X, Yu Y, Tan K, Cui H (2022) Changes of IL-6 and IFN-γ before and after the adverse events related to immune checkpoint inhibitors: a retrospective study. Medicine (Baltimore) 101(46):e31761. 10.1097/MD.0000000000031761<pub-id pub-id-type="pmid">36401365</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/MD.0000000000031761</pub-id><pub-id pub-id-type="pmcid">PMC9678612</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Su</surname><given-names>N</given-names></name><etal/></person-group><article-title>Increased circulating levels of CRP and IL-6 and decreased frequencies of T and B lymphocyte subsets are associated with immune-related adverse events during combination therapy with PD-1 inhibitors for liver cancer</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>906824</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.906824</pub-id><pub-id pub-id-type="pmid">35756643</pub-id><pub-id pub-id-type="pmcid">PMC9232255</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Yu Y, Wang S, Su N et al (2022) Increased circulating levels of CRP and IL-6 and decreased frequencies of T and B lymphocyte subsets are associated with immune-related adverse events during combination therapy with PD-1 inhibitors for liver cancer. Front Oncol 12:906824. 10.3389/fonc.2022.906824<pub-id pub-id-type="pmid">35756643</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fonc.2022.906824</pub-id><pub-id pub-id-type="pmcid">PMC9232255</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Husain</surname><given-names>B</given-names></name><name name-style="western"><surname>Kirchberger</surname><given-names>MC</given-names></name><name name-style="western"><surname>Erdmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Schüpferling</surname><given-names>S</given-names></name><name name-style="western"><surname>Abolhassani</surname><given-names>AR</given-names></name><name name-style="western"><surname>Fröhlich</surname><given-names>W</given-names></name><name name-style="western"><surname>Berking</surname><given-names>C</given-names></name><name name-style="western"><surname>Heinzerling</surname><given-names>L</given-names></name></person-group><article-title>Inflammatory markers in autoimmunity induced by checkpoint inhibitors</article-title><source>J Cancer Res Clin Oncol</source><year>2021</year><volume>147</volume><fpage>1623</fpage><lpage>1630</lpage><pub-id pub-id-type="doi">10.1007/s00432-021-03550-5</pub-id><pub-id pub-id-type="pmid">33837821</pub-id><pub-id pub-id-type="pmcid">PMC8076116</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Husain B, Kirchberger MC, Erdmann M, Schüpferling S, Abolhassani AR, Fröhlich W, Berking C, Heinzerling L (2021) Inflammatory markers in autoimmunity induced by checkpoint inhibitors. J Cancer Res Clin Oncol 147:1623–1630. 10.1007/s00432-021-03550-5<pub-id pub-id-type="pmid">33837821</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00432-021-03550-5</pub-id><pub-id pub-id-type="pmcid">PMC8076116</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>P</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z</given-names></name></person-group><article-title>Serum IL-6 predicts immunotherapy-related adverse and outcome in advanced gastric and esophageal cancer patients with Anti-PD-1 treatment</article-title><source>Front Immunol</source><year>2025</year><volume>16</volume><fpage>1553882</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2025.1553882</pub-id><pub-id pub-id-type="pmid">40519900</pub-id><pub-id pub-id-type="pmcid">PMC12163003</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Ma H, Zhang S, Jiao P, Ding H, Wang F, Zhao Y, Wu J, Guo Z (2025) Serum IL-6 predicts immunotherapy-related adverse and outcome in advanced gastric and esophageal cancer patients with Anti-PD-1 treatment. Front Immunol 16:1553882. 10.3389/fimmu.2025.1553882<pub-id pub-id-type="pmid">40519900</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fimmu.2025.1553882</pub-id><pub-id pub-id-type="pmcid">PMC12163003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shojaie</surname><given-names>L</given-names></name><name name-style="western"><surname>Bogdanov</surname><given-names>JM</given-names></name><name name-style="western"><surname>Alavifard</surname><given-names>H</given-names></name><etal/></person-group><article-title>Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors</article-title><source>Cell Death Dis</source><year>2024</year><volume>15</volume><fpage>140</fpage><pub-id pub-id-type="doi">10.1038/s41419-024-06535-7</pub-id><pub-id pub-id-type="pmid">38355725</pub-id><pub-id pub-id-type="pmcid">PMC10866933</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Shojaie L, Bogdanov JM, Alavifard H et al (2024) Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors. Cell Death Dis 15:140. 10.1038/s41419-024-06535-7<pub-id pub-id-type="pmid">38355725</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41419-024-06535-7</pub-id><pub-id pub-id-type="pmcid">PMC10866933</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Ito T, Yamamoto T, Nishida K et al (2025) Fever following treatment with Atezolizumab plus Bevacizumab predicts liver injury in patients with unresectable hepatocellular carcinoma: a prospective observational analysis. Liver Cancer. 10.1159/000546967<pub-id assigning-authority="pmc" pub-id-type="doi">10.1159/000546967</pub-id><pub-id pub-id-type="pmcid">PMC12266728</pub-id><pub-id pub-id-type="pmid">40678113</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miah</surname><given-names>A</given-names></name><name name-style="western"><surname>Tinoco</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><etal/></person-group><article-title>Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival</article-title><source>J Cancer Res Clin Oncol</source><year>2023</year><volume>149</volume><fpage>2235</fpage><lpage>2242</lpage><pub-id pub-id-type="doi">10.1007/s00432-022-04340-3</pub-id><pub-id pub-id-type="pmid">36070148</pub-id><pub-id pub-id-type="pmcid">PMC10191203</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Miah A, Tinoco G, Zhao S et al (2023) Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. J Cancer Res Clin Oncol 149:2235–2242. 10.1007/s00432-022-04340-3<pub-id pub-id-type="pmid">36070148</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00432-022-04340-3</pub-id><pub-id pub-id-type="pmcid">PMC10191203</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Remawi</surname><given-names>H</given-names></name><name name-style="western"><surname>Lindén</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Pandita</surname><given-names>A</given-names></name><name name-style="western"><surname>Rudin</surname><given-names>A</given-names></name><name name-style="western"><surname>Ny</surname><given-names>L</given-names></name><name name-style="western"><surname>Bjursten</surname><given-names>S</given-names></name><name name-style="western"><surname>Levin</surname><given-names>M</given-names></name></person-group><article-title>Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab</article-title><source>Oncoimmunology</source><year>2025</year><volume>14</volume><fpage>2543510</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2025.2543510</pub-id><pub-id pub-id-type="pmid">40778883</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Al Remawi H, Lindén M, Zhao Z, Pandita A, Rudin A, Ny L, Bjursten S, Levin M (2025) Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab. Oncoimmunology 14:2543510. 10.1080/2162402X.2025.2543510<pub-id pub-id-type="pmid">40778883</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/2162402X.2025.2543510</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaneko</surname><given-names>S</given-names></name><name name-style="western"><surname>Asahina</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors</article-title><source>Hepatol Res</source><year>2023</year><volume>53</volume><fpage>450</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1111/hepr.13878</pub-id><pub-id pub-id-type="pmid">36626292</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Kaneko S, Asahina Y, Nakagawa M et al (2023) Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors. Hepatol Res 53:450–459. 10.1111/hepr.13878<pub-id pub-id-type="pmid">36626292</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/hepr.13878</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Kanda</surname><given-names>T</given-names></name><name name-style="western"><surname>Wakatsuki</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors</article-title><source>Hepatol Int</source><year>2025</year><volume>19</volume><fpage>1221</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1007/s12072-025-10825-3</pub-id><pub-id pub-id-type="pmid">40198524</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Matsumoto K, Kanda T, Wakatsuki J et al (2025) Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors. Hepatol Int 19:1221–1230. 10.1007/s12072-025-10825-3<pub-id pub-id-type="pmid">40198524</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s12072-025-10825-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Purde</surname><given-names>MT</given-names></name><name name-style="western"><surname>Niederer</surname><given-names>R</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>NB</given-names></name><etal/></person-group><article-title>Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients</article-title><source>J Cancer Res Clin Oncol</source><year>2022</year><volume>148</volume><fpage>647</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1007/s00432-021-03870-6</pub-id><pub-id pub-id-type="pmid">34874490</pub-id><pub-id pub-id-type="pmcid">PMC8881258</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Purde MT, Niederer R, Wagner NB et al (2022) Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. J Cancer Res Clin Oncol 148:647–656. 10.1007/s00432-021-03870-6<pub-id pub-id-type="pmid">34874490</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00432-021-03870-6</pub-id><pub-id pub-id-type="pmcid">PMC8881258</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>CH</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>YC</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>HC</given-names></name><name name-style="western"><surname>Wang</surname><given-names>CT</given-names></name><name name-style="western"><surname>Lin</surname><given-names>SM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>AC</given-names></name><name name-style="western"><surname>Yu</surname><given-names>MC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>WC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CC</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>JC</given-names></name></person-group><article-title>Absence of survival impact from hepatitis during immunotherapy in 193 patients with advanced hepatocellular carcinoma - an observational study from Taiwan</article-title><source>J Hepatocell Carcinoma</source><year>2024</year><volume>11</volume><fpage>1875</fpage><lpage>1890</lpage><pub-id pub-id-type="doi">10.2147/JHC.S464105</pub-id><pub-id pub-id-type="pmid">39372711</pub-id><pub-id pub-id-type="pmcid">PMC11456294</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Lin CH, Kuo YC, Kuo HC, Wang CT, Lin SM, Lee AC, Yu MC, Lee WC, Chen CC, Hsieh JC (2024) Absence of survival impact from hepatitis during immunotherapy in 193 patients with advanced hepatocellular carcinoma - an observational study from Taiwan. J Hepatocell Carcinoma 11:1875–1890. 10.2147/JHC.S464105<pub-id pub-id-type="pmid">39372711</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.2147/JHC.S464105</pub-id><pub-id pub-id-type="pmcid">PMC11456294</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swanson</surname><given-names>LA</given-names></name><name name-style="western"><surname>Kassab</surname><given-names>I</given-names></name><name name-style="western"><surname>Tsung</surname><given-names>I</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>RJ</given-names></name></person-group><article-title>Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: a retrospective analysis</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>984940</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.984940</pub-id><pub-id pub-id-type="pmid">36353563</pub-id><pub-id pub-id-type="pmcid">PMC9637844</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Swanson LA, Kassab I, Tsung I, Schneider BJ, Fontana RJ (2022) Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: a retrospective analysis. Front Oncol 12:984940. 10.3389/fonc.2022.984940<pub-id pub-id-type="pmid">36353563</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fonc.2022.984940</pub-id><pub-id pub-id-type="pmcid">PMC9637844</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Ito</surname><given-names>T</given-names></name><name name-style="western"><surname>Hase</surname><given-names>T</given-names></name><etal/></person-group><article-title>Immune-related liver injury is a poor prognostic factor in patients with nonsmall cell lung cancer treated with immune checkpoint inhibitors</article-title><source>Cancer Invest</source><year>2022</year><volume>40</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1080/07357907.2021.1994586</pub-id><pub-id pub-id-type="pmid">34658277</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Yamamoto T, Ito T, Hase T et al (2022) Immune-related liver injury is a poor prognostic factor in patients with nonsmall cell lung cancer treated with immune checkpoint inhibitors. Cancer Invest 40:189–198. 10.1080/07357907.2021.1994586<pub-id pub-id-type="pmid">34658277</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/07357907.2021.1994586</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X</given-names></name></person-group><article-title>Liver injury and its impact on prognosis in patients with HBV-related hepatocellular carcinoma undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors</article-title><source>J Hepatocell Carcinoma</source><year>2024</year><volume>11</volume><fpage>207</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.2147/JHC.S431191</pub-id><pub-id pub-id-type="pmid">38283694</pub-id><pub-id pub-id-type="pmcid">PMC10822136</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Shen J, Wang X, Yang G, Li L, Fu J, Xu W, Zhang Q, Pan X (2024) Liver injury and its impact on prognosis in patients with HBV-related hepatocellular carcinoma undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors. J Hepatocell Carcinoma 11:207–217. 10.2147/JHC.S431191<pub-id pub-id-type="pmid">38283694</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.2147/JHC.S431191</pub-id><pub-id pub-id-type="pmcid">PMC10822136</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>DY</given-names></name><name name-style="western"><surname>Salem</surname><given-names>JE</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>JV</given-names></name><etal/></person-group><article-title>Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis</article-title><source>JAMA Oncol</source><year>2018</year><volume>4</volume><fpage>1721</fpage><lpage>1728</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2018.3923</pub-id><pub-id pub-id-type="pmid">30242316</pub-id><pub-id pub-id-type="pmcid">PMC6440712</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721–1728. 10.1001/jamaoncol.2018.3923<pub-id pub-id-type="pmid">30242316</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1001/jamaoncol.2018.3923</pub-id><pub-id pub-id-type="pmcid">PMC6440712</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Delayed immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database</article-title><source>J Clin Oncol</source><year>2025</year><volume>43</volume><fpage>e24093</fpage><lpage>e24093</lpage><pub-id pub-id-type="doi">10.1200/JCO.2025.43.16_suppl.e24093</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Hong Z, Guan Y, Xie H, Chen Y, Zhang Y, Zhang B, Wang J (2025) Delayed immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database. J Clin Oncol 43:e24093–e24093. 10.1200/JCO.2025.43.16_suppl.e24093</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>H</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury</article-title><source>Clin Exp Med</source><year>2025</year><volume>25</volume><fpage>288</fpage><pub-id pub-id-type="doi">10.1007/s10238-025-01721-z</pub-id><pub-id pub-id-type="pmid">40788551</pub-id><pub-id pub-id-type="pmcid">PMC12339640</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Hu H, Shen X, Chen J (2025) Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury. Clin Exp Med 25:288. 10.1007/s10238-025-01721-z<pub-id pub-id-type="pmid">40788551</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s10238-025-01721-z</pub-id><pub-id pub-id-type="pmcid">PMC12339640</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>C</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S</given-names></name></person-group><article-title>Tacrolimus and mycophenolate mofetil in corticosteroid-resistant hepatitis secondary to tislelizumab: a case report</article-title><source>Front Oncol</source><year>2025</year><volume>15</volume><fpage>1385794</fpage><pub-id pub-id-type="doi">10.3389/fonc.2025.1385794</pub-id><pub-id pub-id-type="pmid">39963104</pub-id><pub-id pub-id-type="pmcid">PMC11830594</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Jiang C, Guo S (2025) Tacrolimus and mycophenolate mofetil in corticosteroid-resistant hepatitis secondary to tislelizumab: a case report. Front Oncol 15:1385794. 10.3389/fonc.2025.1385794<pub-id pub-id-type="pmid">39963104</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fonc.2025.1385794</pub-id><pub-id pub-id-type="pmcid">PMC11830594</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>K</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>J</given-names></name><name name-style="western"><surname>Ninomiya</surname><given-names>M</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>T</given-names></name><name name-style="western"><surname>Sano</surname><given-names>A</given-names></name><name name-style="western"><surname>Tsuruoka</surname><given-names>M</given-names></name><name name-style="western"><surname>Onuki</surname><given-names>M</given-names></name><name name-style="western"><surname>Sawahashi</surname><given-names>S</given-names></name><name name-style="western"><surname>Ouchi</surname><given-names>K</given-names></name><name name-style="western"><surname>Masamune</surname><given-names>A</given-names></name></person-group><article-title>Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil</article-title><source>Clin J Gastroenterol</source><year>2023</year><volume>16</volume><fpage>720</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1007/s12328-023-01832-8</pub-id><pub-id pub-id-type="pmid">37480423</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Sato K, Inoue J, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Onuki M, Sawahashi S, Ouchi K, Masamune A (2023) Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil. Clin J Gastroenterol 16:720–725. 10.1007/s12328-023-01832-8<pub-id pub-id-type="pmid">37480423</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s12328-023-01832-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirasawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yoshimura</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsui</surname><given-names>H</given-names></name><etal/></person-group><article-title>A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy</article-title><source>Medicine (Baltimore)</source><year>2021</year><volume>100</volume><fpage>e25774</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000025774</pub-id><pub-id pub-id-type="pmid">34114983</pub-id><pub-id pub-id-type="pmcid">PMC8202549</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Hirasawa Y, Yoshimura K, Matsui H et al (2021) A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. Medicine (Baltimore) 100:e25774. 10.1097/MD.0000000000025774<pub-id pub-id-type="pmid">34114983</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/MD.0000000000025774</pub-id><pub-id pub-id-type="pmcid">PMC8202549</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Medik</surname><given-names>YB</given-names></name><name name-style="western"><surname>Patel</surname><given-names>B</given-names></name><etal/></person-group><article-title>Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration</article-title><source>J Exp Med</source><year>2023</year><volume>220</volume><fpage>e20221333</fpage><pub-id pub-id-type="doi">10.1084/jem.20221333</pub-id><pub-id pub-id-type="pmid">36367776</pub-id><pub-id pub-id-type="pmcid">PMC9664499</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Zhou Y, Medik YB, Patel B et al (2023) Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. J Exp Med 220:e20221333. 10.1084/jem.20221333<pub-id pub-id-type="pmid">36367776</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1084/jem.20221333</pub-id><pub-id pub-id-type="pmcid">PMC9664499</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daoudlarian</surname><given-names>D</given-names></name><name name-style="western"><surname>Segot</surname><given-names>A</given-names></name><name name-style="western"><surname>Latifyan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy</article-title><source>Ann Oncol</source><year>2024</year><volume>36</volume><fpage>444</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2024.12.004</pub-id><pub-id pub-id-type="pmid">39701282</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Daoudlarian D, Segot A, Latifyan S et al (2024) Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy. Ann Oncol 36:444–459. 10.1016/j.annonc.2024.12.004<pub-id pub-id-type="pmid">39701282</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.annonc.2024.12.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fa’ak</surname><given-names>F</given-names></name><name name-style="western"><surname>Buni</surname><given-names>M</given-names></name><name name-style="western"><surname>Falohun</surname><given-names>A</given-names></name><etal/></person-group><article-title>Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events</article-title><source>J Immunother Cancer</source><year>2023</year><volume>11</volume><fpage>e006814</fpage><pub-id pub-id-type="doi">10.1136/jitc-2023-006814</pub-id><pub-id pub-id-type="pmid">37328287</pub-id><pub-id pub-id-type="pmcid">PMC10277540</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Fa’ak F, Buni M, Falohun A et al (2023) Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J Immunother Cancer 11:e006814. 10.1136/jitc-2023-006814<pub-id pub-id-type="pmid">37328287</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/jitc-2023-006814</pub-id><pub-id pub-id-type="pmcid">PMC10277540</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stroud</surname><given-names>CR</given-names></name><name name-style="western"><surname>Hegde</surname><given-names>A</given-names></name><name name-style="western"><surname>Cherry</surname><given-names>C</given-names></name><name name-style="western"><surname>Naqash</surname><given-names>AR</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N</given-names></name><name name-style="western"><surname>Addepalli</surname><given-names>S</given-names></name><name name-style="western"><surname>Cherukuri</surname><given-names>S</given-names></name><name name-style="western"><surname>Parent</surname><given-names>T</given-names></name><name name-style="western"><surname>Hardin</surname><given-names>J</given-names></name><name name-style="western"><surname>Walker</surname><given-names>P</given-names></name></person-group><article-title>Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade</article-title><source>J Oncol Pharm Pract</source><year>2019</year><volume>25</volume><fpage>551</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1177/1078155217745144</pub-id><pub-id pub-id-type="pmid">29207939</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Stroud CR, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, Cherukuri S, Parent T, Hardin J, Walker P (2019) Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract 25:551–557. 10.1177/1078155217745144<pub-id pub-id-type="pmid">29207939</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1177/1078155217745144</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>SB</given-names></name><name name-style="western"><surname>Vembar</surname><given-names>P</given-names></name><name name-style="western"><surname>Sukumaran</surname><given-names>S</given-names></name><name name-style="western"><surname>Gunawardane</surname><given-names>D</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>T</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A</given-names></name></person-group><article-title>Tocilizumab in grade 4 hepatitis secondary to immune checkpoint inhibitor: a case report and review of the literature</article-title><source>Immunotherapy</source><year>2023</year><volume>15</volume><fpage>1125</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.2217/imt-2023-0085</pub-id><pub-id pub-id-type="pmid">37401340</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Ali SB, Vembar P, Sukumaran S, Gunawardane D, Hughes T, Smith A (2023) Tocilizumab in grade 4 hepatitis secondary to immune checkpoint inhibitor: a case report and review of the literature. Immunotherapy 15:1125–1132. 10.2217/imt-2023-0085<pub-id pub-id-type="pmid">37401340</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.2217/imt-2023-0085</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyles</surname><given-names>L</given-names></name><name name-style="western"><surname>Farmer</surname><given-names>R</given-names></name><name name-style="western"><surname>Abougergi</surname><given-names>M</given-names></name></person-group><article-title>A potential new use for Tocilizumab: refractory checkpoint inhibitor hepatitis</article-title><source>ACG Case Rep J</source><year>2023</year><volume>10</volume><fpage>e01162</fpage><pub-id pub-id-type="doi">10.14309/crj.0000000000001162</pub-id><pub-id pub-id-type="pmid">37753105</pub-id><pub-id pub-id-type="pmcid">PMC10519460</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Lyles L, Farmer R, Abougergi M (2023) A potential new use for Tocilizumab: refractory checkpoint inhibitor hepatitis. ACG Case Rep J 10:e01162. 10.14309/crj.0000000000001162<pub-id pub-id-type="pmid">37753105</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.14309/crj.0000000000001162</pub-id><pub-id pub-id-type="pmcid">PMC10519460</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moi</surname><given-names>L</given-names></name><name name-style="western"><surname>Bouchaab</surname><given-names>H</given-names></name><name name-style="western"><surname>Mederos</surname><given-names>N</given-names></name><name name-style="western"><surname>Nguyen-Ngoc</surname><given-names>T</given-names></name><name name-style="western"><surname>Perreau</surname><given-names>M</given-names></name><name name-style="western"><surname>Fenwick</surname><given-names>C</given-names></name><name name-style="western"><surname>Vaucher</surname><given-names>J</given-names></name><name name-style="western"><surname>Sempoux</surname><given-names>C</given-names></name><name name-style="western"><surname>Peters</surname><given-names>S</given-names></name><name name-style="western"><surname>Obeid</surname><given-names>M</given-names></name></person-group><article-title>Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis</article-title><source>J Thorac Oncol</source><year>2021</year><volume>16</volume><fpage>318</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2020.09.007</pub-id><pub-id pub-id-type="pmid">32956849</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Moi L, Bouchaab H, Mederos N, Nguyen-Ngoc T, Perreau M, Fenwick C, Vaucher J, Sempoux C, Peters S, Obeid M (2021) Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis. J Thorac Oncol 16:318–326. 10.1016/j.jtho.2020.09.007<pub-id pub-id-type="pmid">32956849</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jtho.2020.09.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimitriou</surname><given-names>F</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>S</given-names></name><name name-style="western"><surname>Menzies</surname><given-names>AM</given-names></name><name name-style="western"><surname>Dummer</surname><given-names>R</given-names></name><name name-style="western"><surname>Long</surname><given-names>GV</given-names></name></person-group><article-title>Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy</article-title><source>Eur J Cancer</source><year>2021</year><volume>157</volume><fpage>214</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2021.08.031</pub-id><pub-id pub-id-type="pmid">34536945</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Dimitriou F, Hogan S, Menzies AM, Dummer R, Long GV (2021) Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. Eur J Cancer 157:214–224. 10.1016/j.ejca.2021.08.031<pub-id pub-id-type="pmid">34536945</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.ejca.2021.08.031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Successful rechallenge of immune checkpoint inhibitors after severe immune-related hepatitis, thyroiditis and hypophysitis in TMB-high NSCLC: a case report</article-title><source>Transl Lung Cancer Res</source><year>2025</year><volume>14</volume><fpage>2875</fpage><lpage>2879</lpage><pub-id pub-id-type="doi">10.21037/tlcr-2025-341</pub-id><pub-id pub-id-type="pmid">40799443</pub-id><pub-id pub-id-type="pmcid">PMC12337046</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Zhou Z, Wang H (2025) Successful rechallenge of immune checkpoint inhibitors after severe immune-related hepatitis, thyroiditis and hypophysitis in TMB-high NSCLC: a case report. Transl Lung Cancer Res 14:2875–2879. 10.21037/tlcr-2025-341<pub-id pub-id-type="pmid">40799443</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.21037/tlcr-2025-341</pub-id><pub-id pub-id-type="pmcid">PMC12337046</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagpal</surname><given-names>C</given-names></name><name name-style="western"><surname>Rastogi</surname><given-names>S</given-names></name><name name-style="western"><surname>Shamim</surname><given-names>SA</given-names></name><name name-style="western"><surname>Prakash</surname><given-names>S</given-names></name></person-group><article-title>Re-challenge of immune checkpoint inhibitor pembrolizumab with concurrent tocilizumab after prior grade 3 pneumonitis</article-title><source>Ecancermedicalscience</source><year>2023</year><volume>17</volume><fpage>1644</fpage><pub-id pub-id-type="doi">10.3332/ecancer.2023.1644</pub-id><pub-id pub-id-type="pmid">38414933</pub-id><pub-id pub-id-type="pmcid">PMC10898886</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Nagpal C, Rastogi S, Shamim SA, Prakash S (2023) Re-challenge of immune checkpoint inhibitor pembrolizumab with concurrent tocilizumab after prior grade 3 pneumonitis. Ecancermedicalscience 17:1644. 10.3332/ecancer.2023.1644<pub-id pub-id-type="pmid">38414933</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3332/ecancer.2023.1644</pub-id><pub-id pub-id-type="pmcid">PMC10898886</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliva</surname><given-names>KN</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>L</given-names></name><name name-style="western"><surname>Heinzerling</surname><given-names>L</given-names></name><etal/></person-group><article-title>Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis</article-title><source>J Immunother Cancer</source><year>2025</year><volume>13</volume><fpage>e013038</fpage><pub-id pub-id-type="doi">10.1136/jitc-2025-013038</pub-id><pub-id pub-id-type="pmid">40992785</pub-id><pub-id pub-id-type="pmcid">PMC12458706</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Oliva KN, Arnold L, Heinzerling L et al (2025) Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis. J Immunother Cancer 13:e013038. 10.1136/jitc-2025-013038<pub-id pub-id-type="pmid">40992785</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/jitc-2025-013038</pub-id><pub-id pub-id-type="pmcid">PMC12458706</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>